Method for evaluating a patients biological condition

ABSTRACT

This invention is concerned with a method for evaluating the dynamic biological state of a patient, said method, which involves measuring several elements or substances contained in the blood and interpreting results of the measurements carried out, comprising the following steps (1°) taking a sample of blood from the patient to be examined; (2°) determining hematic substances serving as metabolic and/or tissue parameters; (3°) measuring, on the basis of the determination of step (2°), the totality or part of indexes J1 to J157 defined in the disclosure; and (4°) comparing at least part of said indexes J1 to J157 with similar values obtained at steps (2°) and (3°) on subjects already identified as healthy, to dynamically assess the biological state of the patient to be examined. This invention is also concerned with a software product for executing on a computer steps (3°) and (4°).

FIELD OF THE INVENTION

This invention is concerned with a new method for evaluating ordiagnosing the dynamic biological state of a patient (or a healthysubject), in view to anticipate and to watch its evolution with thepassing of time in order to prevent foreseeable abnormalities and/or tocorrect revealed defects.

PRIOR ART

Today, every biological method is destined to show the presence orabsence of an illness and, if an illness does exist, to specify itsnature and degree of gravity. In order to appreciate the optionalpathological state of a patient (i) the amount of one or severalparameters is determined in a body fluid taken from a patient, forinstance blood, plasma, serum, saliva, or urine, then (ii) said amountis compared to the normal value (in general a normal range) which isknown from a healthy patient or a pool of healthy patients.

Such a route is substantially of the binary type—yes or no—and static inthe sense that the concerned parameter is connected to its sole normalvalue. That route does not provide any indication regarding themodalities of modifications of said amount and its upholding within thenormality range. It allows showing the humeral abnormalities of thepatient, but does not allow to appreciate his dynamic biological stateand to foresee its evolution with the passing of time. It would surelybe more convenient to propose a new technique implying a reading of theternary or higher multivariable type, in order to make available adynamic approach for an overall view of evolution.

AIM OF THE INVENTION

The aim is to provide a novel technical solution allowing to obviate theabove cited defects of the prior art. That novel technical solutioncomprises determining several metabolic and/or tissular parameters,which are known and referenced, measuring multiple indexes from saidparameters and comparing said indexes with values obtained from healthypatients or analogous values deduced from medians of internationalreferences which are recognized for the different parameters used forsubjects who are ideally free of those defects which are looked for.

SUBJECT OF THE INVENTION

The novel technical solution which is provided according to theinvention ensures a method for evaluating (or diagnosing) the dynamicbiological state of a patient (either healthy or ill), both on thestructure and function points of view, and its evolution with thepassing of time in view to correct observed defects, said method, whichinvolves measuring several elements or substances present in blood andinterpreting results of performed measures, comprising the followingsteps:

-   (1°) providing the blood previously taken from a patient;-   (2°) determining in vitro, from said blood, hematic substances as    metabolic and/or tissular parameters:    -   number of red blood cells (GR),    -   number of leukocytes (GB),    -   hemoglobin (HG),    -   number of neutrophils,    -   number of eosinophils,    -   number of lymphocytes,    -   number of monocytes,    -   number of platelets,    -   lactate dehydrogenase (LDH),    -   creatine phosphokinase (CPK),    -   thyroid-stimulating hormone (TSH),    -   alkaline phosphatases,    -   liver (H1 and H2), bone (O1) and/or intestine (I1, I2 and I3)        isoenzymes,    -   osteocalcin,    -   potassium and calcium, and optionally, at least one of the        following substances:    -   carcinoembryonic antigen (CEA),    -   one or several CA15-3, CA125 and CA19-9 markers,    -   acid phosphatases, in particular prostatic acid phosphatase        (PAP),    -   prostate specific antigen (PSA),    -   hourly sedimentation rate (ESR₁),    -   bihourly sedimentation rate (ESR₂),    -   thyroid hormones, in particular triiodothyronine (FT3) and        thyroxine (FT4),    -   γ-glutamyl transpeptidases,    -   transaminases,    -   chlorides and sodium, and    -   adrenocorticotropic hormone (ACTH);-   (3°) measuring, from step (2°), at least one index selected from the    group consisting of following indexes J1-J157:-   J1 the so-called genital ratio index, which is the ratio red blood    cells/leukocytes,-   J2 the so-called genital-thyroid ratio index, which is the ratio    neutrophils/lymphocytes,-   J3 the so-called adaptation index, which is the ratio    eosinophils/monocytes,-   J3 being such that J3=eosinophils/monocytes=ACTH/FSH,-   J4 the so-called thyroid index, which is the ratio LDH/CPK,-   J5 the so-called estrogenic index, which is the ratio    TSH/osteocalcin,-   J6 the so-called growth index, which is the ratio bone isoenzymes of    the alkaline phosphatases/osteocalcin, (O1/osteocalcin),-   J7 the so-called turnover index, which is the product TSH×O1-   J8 the so-called fibrosis index, J8 being defined by the relation-   J8=(TSH)²(osteocalcin)³/100,-   J9 the so-called index of thyroid involvement, which is the ratio CA    15-3/CEA,-   J10 the so-called index of follicular involvement, which is the    ratio CA 125/CEA,-   J11 the so-called index of metabolic-hypothalamic involvement, which    is the ratio CA19-9/CEA,-   J12 the so-called pancreatic index, which is the ratio PAP/PSA,-   J13 the so-called global TRH index of adaptation, which is the ratio    CA19-9/TSH,-   J14 the so-called index of leukocytes mobilization, J14 being    defined by the relation    J14=(platelets×neutrophils×HG)/(30×leukocytes),-   J15 the so-called index of platelets mobilization, J15 being defined    by the relation J15=platelets/(60×red blood cells),-   J16 the so-called index of thyroid reactivating activity, which is    the ratio monocytes/lymphocytes,-   J17 the so-called structure/function ratio index, J17 being defined    by the relation    J17=(neutrophils+basophils+monocytes)/(eosinophils×lymphocytes),-   J18 the so-called index of estrogenic fraction # 1, which is the    ratio lymphocytes/osteocalcin,-   J19 the so-called index of estrogenic fraction #2, which is the    ratio neutrophils/monocytes,-   J20 the so-called index of metabolic estrogenic fraction, which is    the ratio LDH/osteocalcin,-   J21 the so-called index of thyroid mobilization of bone metabolism,    which is the ratio LDH/bone isoenzymes fraction of the alkaline    phosphatases,-   J22 the so-called index of thyroid mobilization of bone endocrine    metabolism, which is the ratio TSH/bone isoenzymes fraction of the    alkaline phosphatases,-   J23 the so-called index of relative osteomuscular metabolic    activity, which is the ratio CPK/bone isoenzymes fraction of the    alkaline phosphatases,-   J24 the so-called index of thyroid bone metabolic activity, which is    the ratio CPK/osteocalcin,-   J25 the so-called catabolism/anabolism ratio index, J25 being the    ratio J2/J1,-   J26 the so-called index of circulating cortisol, J26 being the ratio    J25/J3,-   J27 the so-called androgenic index, J27 being the ratio J1/J3,-   J28 the so-called adrenal cortex index, J28 being the ratio J26/J27,-   J29 the so-called index of adrenal cortex permissiveness, J29 being    the ratio J1/J27,-   J30 the so-called index of aromatization of estrogens, J30 being the    ratio J29/J1,-   J31 the so-called level of catabolism, J31 being the ratio J4/J28,-   J32 the so-called level of anabolism, J32 being the ratio J31/J25,-   J33 the so-called level of metabolic activity efficiency, J33 being    defined by the relation J33=(J32+J31)×100/2.25,-   J34 the so-called index of bone remodeling, which is the product    TSH×J6,-   J35 the so-called index of nuclear membrane activity, J35 being the    ratio J5/J6,-   J36 the so-called adjusted growth index, J36 being the ratio J6/J7,-   J37 the so-called anti-growth index, J37 being the ratio 1/J36,-   J38 the so-called somatostatin index, J38 being the ratio J37/J26,-   J39 the so-called prolactin index, J39 being defined by the relation-   J39=(J38/J6)×TSH,-   J40 the so-called level of membrane expansion, J40 being the product    J31×J36,-   J41 the so-called level of structural expansion, J41 being the    product J32×J35,-   J42 the so-called apoptosis index, J42 being the ratio J41/J40,-   J43 the so-called adjusted apoptosis index, J43 being the ratio    J42/J35,-   J44 the so-called level of membrane fracture, J44 being defined by    the relation J44=J33/(TSH×J7),-   J45 the so-called necrosis index, J45 being the ratio J44/J42,-   J46 the so-called level of activity of total androgens, J46 being    the product J5×J1-   J47 the so-called rate of adrenal cortex androgens, J47 being    defined by the relation J47=J46/(1+J27),-   J48 the so-called rate of genital androgens, J48 being defined by    the relation J48=(J46−J47),-   J49 the so-called progesterone index, J49 being defined by the    relation-   J49=J5/(J48×J3),-   J50 the so-called level of activity of genital estrogens, J50 being    defined by the relation J50=J5/(1+J30),-   J51 the so-called rate of aromatized estrogens, J51 being defined by    the relation J51=J5−J50,-   JJ53 the so-called folliculin index, J53 being defined by the    relation J53=20×(J5/J49),-   J54 the so-called insulin index, J54 being defined by the relation    J54=(100×J25)/(J7×TSH),-   J55 the so-called demyelinization index, J55 being defined by the    relation J55−J541(J36×J6),-   J56 the so-called index of DNA fracture, J56 being defined by the    relation J56=(100×J5×J6×J41)/(J7×J35×J42×J45),-   J57 the so-called index of nucleocytoplasmic pathogenicity, J57    being defined by the relation J57=(1.7×J56)/J44,-   J58 the so-called index of cellular fracture, J58 being defined by    the relation J58=2.5×J44×J56/J45,-   J59 the so-called index of carcinogenesis, J59 is the ratio J57/J42,-   J60 the so-called index of comparative carcinogenesis, J60 being    defined by the relation J60=(10×J58)/J43,-   J61 the so-called index of active cellular permeability, J61 being    defined by the relation J61=J6×J34/J54,-   J62 the so-called index of adjusted active cellular permeability,    J62 being defined by the relation J62=(J61×J29)/J26,-   J63 the so-called index of passive cellular permeability, J63 being    defined by the relation J63=J45×J35×J68×10 (wherein J68 is defined    as indicated below),-   J64 the so-called index of active intracellular osmolar gradient,    J64 being defined by the relation J64=100×J54×J40×J35/J3,-   J65 the so-called index of adjusted active intracellular osmolar    gradient, J65 being defined by the relation J65=(J64×J29)/J26,-   J66 the so-called index of passive intracellular osmolar gradient,    J66 being defined by the relation J66=(10×J43×J53)/(J45×J8),-   J67 the so-called oxidation-reduction index, J67 being defined by    the relation-   J67=(100×J45×J40×J41×J54)/(J71×J8×J38), (wherein J71 is defined as    indicated below),-   J68 the so-called index of corticoadrenal adaptation/permissiveness,    J68 being defined by the relation J68=J26−J29−J28,-   J69 the so-called adaptogenic index which is the ratio K/Ca,-   J70 the so-called βMSH/αMSH index, (differential    melanocyte-stimulating hormones), J70 being the ratio J4/J69,-   J71 the so-called apoptosis bis index, J71 being defined by the    relation-   J71=J35/(J36×J25),-   J72 the so-called amylosis index, J72 being defined by the relation-   J72=(J38×J53×J55×TSH)/(J4×J5×J54),-   J73 the so-called index of amylosis risk, J73 being the ratio    J8/J67,-   J74 the so-called index of insulin resistance, J74 being the ratio    J38/J54,-   J75 the so-called upstream index # 1, J75 being the ratio J4/J9,-   J76 the so-called upstream index #2, J76 being the ratio J4/J10,-   J77 the so-called upstream index #3, J77 being the ratio J4/J11,-   J78 the so-called global upstream index #1, J78 being the ratio    J75/J76,-   J79 the so-called global upstream index #2, J79 being the ratio    J75/J77,-   J80 the so-called global upstream index #3, J80 being the ratio    J76/J77,-   J81 the so-called index of thyroid output #1, J81 being the ratio    J4/TSH,-   J82 the so-called index of free radicals, J82 being the ratio    J67/J54,-   J83 the so-called adjusted index of free radicals, J83 being defined    by the relation J83=(J67+J64)/(J54+J74),-   J84 the so-called comparative index of free radicals, J84 being    defined by the relation J84=(J67+(100×J40)/(J54+J74),-   J85 the so-called index of free radical nocivity, J85 being defined    by the relation J85=((J82+J83+J84)×J56)/(3×J71),-   J86 the so-called adjusted apoptosis index (B), J86 being the ratio    J71/J35,-   J87 the so-called index of active histamine, J87 being defined by    the relation-   J87=(eosinophils×platelets×J3)/J52,-   J88 the so-called index of potential histamine, J88 being defined by    the relation J88=(J87×J63)/(potassium×J70)-   J89 the so-called TRH index, J89 being the ratio TSH/FT4, J90 the    so-called index of relative intrathyroid TRH activity, which is the    ratio FT3/FT4,-   J91 the so-called index of carcinogenic expansion, J91 being the    ratio J60/J59,-   J92 the so-called index of cancer potential, J92 being the product    J91×J54×J85,-   J93 the so-called adenosis index, J93 being the ratio J8/J91,-   J94 the so-called ischemia reperfusion index, J94 being defined by    the relation J94=10×J34×J43/J33,-   J95 the so-called thrombogenic index, J95 being defined by the    relation J95=10×J34×J42×J45/J33,-   J96 the so-called thrombotic index, J96 being defined by the    relation J96=J95×J87×J1/10,-   J97 the so-called adjusted genital ratio index, J97 being defined by    the relation J97=(J14×Red cells)/(Leukocytes×J15)=J14×J1/J15,-   J98 the so-called musculotropic index, J98 being defined by the    relation J98=J97×(CPK/O1),-   J99 the so-called adjusted estrogenic index, J99 being defined by    the relation J99=(J5×(osteocalcin+1)/(osteocalcin+1−J98)),-   J100 the so-called genital androgeny index, J100 being defined by    the relation J100=(J98/J81)×J99×(J97)²/(J3+J97),-   J101 the so-called comparative genital androgeny index, J101 being    defined by the relation J101=(2×(TSH)²×CPK)/(J4×osteocalcin×01),-   J102 the so-called “starter” index, J102 being the ratio J14/J15,-   J103 the so-called adjusted index of thyroid reactivating activity,    J103 being the product J16×J2,-   J104 the so-called pro-inflammatory index, J104 being the product    J103×J69,-   J105 the so-called index of inflammation, J105 being the product    J104×J45,-   J106 the so-called comparative index of inflammation, J106 being    defined by the relation J106=J105/(((ESR₂/2)+ESR₁)/2)/ESR₁,-   J107 the so-called interleukin 1 index, J107 being defined by the    relation J107=(J16×J38)/(J103×J37),-   J108 the so-called DHEA index, J108 being defined by the relation    J108=(J29×J30×J47×J51×J98×1000)/(J49×J27×J100),-   J109 the so-called serotonin index, J109 being defined by the    relation J109=(10×J102)/(J54×J74),-   J110 the so-called adjusted demyelinization index, J110 being the    product J55×J102,-   J111 the so-called expansiveness index #1, J111 being the ratio    J36/J35, J112 the so-called expansiveness index #2, J112 being the    ratio J40/J41,-   J113 the so-called global expansiveness index, J113 being defined by    the relation J113=(J111×J112)/J45,-   J114 the so-called ACTH index, J114 being the ratio J108/J26,-   J115 the so-called PTH index, J115 being defined by the relation    J115=(calcium×osteocalcin×TSH)/J4,-   J116 the so-called index of gonadotropic output, J116 being defined    by the relation J116=1/(J×J53),-   J117 the so-called index of pelvic congestion, J117 being defined by    the relation J117=(J59/J60)×(J94/J33),-   J118 the so-called index of splanchnic congestion, J118 being the    ratio J117/J14,-   J119 the so-called growth score index, J119 being defined by the    relation J119=(J6×J37)/(J36×J38),-   J120 the so-called GH growth score index, J120 being defined by the    relation J120=(J6×J37)/J36,-   J121 the so-called TRH/TSH ratio index, J121 being the ratio    J72/J93,-   J122 the so-called index of thyroid efficiency, J122 being the ratio    J4/J2,-   J123 the so-called index of relative thyroid efficiency, J123 being    the ratio J122/J81,-   J124 the so-called index of oxidation, J124 being defined by the    relation J124=(100×J36×J54×J122)/(J74×J26),-   J125 the so-called index of reduction, J125 being the ratio    J124/J67,-   J126 the so-called pro-amyloid index, J126 being the product    J125×J74,-   J127 the so-called index of amyloid risk, J127 being the ratio    J8/J124,-   J128 the so-called index of thyroid output #2, J128 being the    product J2×J4,-   J129 the so-called comparative index of thyroid output, J129 being    the ratio J128/J81,-   J130 the so-called index of estrogenic fraction #3, J130 being the    ratio 1/J1,-   J131 the so-called index of estrogenic fraction #4, J131 being the    product J18×J19,-   J132 the so-called index of estrogenic fraction #5, J132 being the    product J19×J130,-   J133 the so-called general index of estrogenic fraction, J133 being    the product J18×J19×J130,-   J134 the so-called index of estrogenic fraction #6, J134 being    defined by the relation J134=1/(osteocalcin×J2),-   J135 the so-called index of estrogenic fraction #7, J135 being the    product J18×J19×J134,-   J136 the so-called index of estrogenic fraction #8, J136 being the    ratio J2/osteocalcin,-   J137 the so-called general quantitative estrogenic index, J137 being    the product (J18+J19)×(leukocytes/100),-   J138 the so-called index of specific estrogenic fraction, J138 being    the product J5×(J98+1),-   J139 the so-called comparative estrogenic index #1, J139 being the    ratio J133/(J5×100),-   J140 the so-called comparative estrogenic index #2, J140 being the    ratio J133/(J99×100),-   J141 the so-called global comparative estrogenic index, J141 being    the ratio J133/(J5×J99×100),-   J142 the so-called index of somatotropic estrogenic output, J142    being the ratio J133/J144 (where J144 is defined as indicated    below),-   J143 the so-called index of quantitative organotissular estrogenic    output, J143 being the ratio J137/J144 (where J144 is defined    below),-   J144 the so-called FSH index #1, J144 being the ratio J114/J3,-   J145 the so-called LH index #1, J145 being the product J114×J27,-   J146 the so-called FSH index #2, J146 being the ratio J145/J1,-   J147 the so-called LH index #2, J147 being the product J144×J1,-   J148 the so-called index of progesterone output, J148 being the    ratio J49/J138,-   J149 the so-called ketonic index, J149 being the ratio J102/J54,-   J150 the so-called index of total subliminal TRH, J150 being the    product TSH×(CA19-9)×J90,-   J151 the so-called index of active carcinogenesis, J151 being the    product J59×J113,-   J152 the so-called comparative index of active carcinogenesis, J152    being the product J60×J113,-   J153 the so-called gonadothyrotropic index, J153 being the ratio    TSH/J2,-   J154 the so-called index of global tissular estrogenic fraction,    J154 being the ratio J140/J139,-   J155 the so-called index of muscle destruction, J155 being the ratio    J36/J101,-   J156 the so-called amyloid score index, J156 being defined by the    relation J156=(J2×J53×J72×J94×J110×J126×J127)/(J4×J5×J67×J19×J20),-   J157 the so-called adjusted necrosis index, J157 being the product    LDH×J45; and,-   (4°) comparing at least one of the J1-J157 indexes with the    corresponding result obtained according to steps (2°) and (3°) with    human beings already recognized as being healthy, in order to    appreciate dynamically the biological state of the patient to be    tested.

According to a further aspect of the invention, a software product isprovided, which allows to carry out steps (3°) and (4°) of said method.Said software product, which is (directly or indirectly loadable) in the(internal or auxiliary) memory of a digital or analog computer,comprises portions of computer code to perform steps (3°) and (4°) ofthe method regarding the evaluation of the dynamic biological state of apatient.

DETAILED DESCRIPTION OF THE INVENTION

The method according to this invention provides a value, which is (i)dynamic vis-à-vis the static image given by the binary frame of theprior art teaching, (ii) diagnostic with respect to the true biologicaletiology of each patient vis-à-vis the specific etiology of the illness,and (iii) predictive which is highly more precise both in the pathogenicrisk and the pathological future.

Carrying out the present method requires a minimal number of indexesexploring the functions involved in the symptomatology and/or pathologyof the patient to be tested. To that aim it is interesting to determinein step (2°) one or several hematic substances among those that follow:

-   -   (a) those intervening as essential parameters:    -   number of red blood cells (GR),    -   number of leukocytes (GB),    -   hemoglobin (HG),    -   number of neutrophils,    -   number of eosinophils,    -   number of lymphocytes,    -   number of monocytes,    -   number of platelets,    -   lactate dehydrogenase (LDH),    -   creatine phosphokinase (CPK),    -   thyroid-stimulating hormone (TSH),    -   alkaline phosphatases,    -   liver (H1 and H2), bone (O1) and/or intestine (I1, I2 and I3)        isoenzymes,    -   osteocalcin,    -   potassium and calcium;

-   (b) those intervening as specific parameters vis-à-vis certain    pathologies:    -   carcinoembryonic antigen (CEA),    -   one or several CA15-3, CA125 and CA19-9 markers,    -   acid phosphatases, in particular prostatic acid phosphatase        (PAP),    -   prostate specific antigen (PSA);

-   (c) those intervening as supplemental parameters:    -   hourly sedimentation rate (ESR₁),    -   bihourly sedimentation rate (ESR₂),    -   thyroid hormones, in particular triiodothyronine (FT3) and        thyroxine (FT4); and,

-   (d) those useful for orienting the choice of an index or a group of    indexes:    -   γ-glutamyl transpeptidases,    -   transaminases,    -   chlorides and sodium, and    -   adrenocorticotropic hormone (ACTH).

In practice, parameters belonging to the above groups (a), (b) and (c)are determined in vitro. Advantageously, are determined:

-   -   the totality of parameters (a),    -   the totality or a portion of the parameters (b), and    -   at least one of the parameters (c) or their totality, in view of        the symtomatology and/or pathology of the human being to be        tested.

In step (3°) of the method according to the invention, it is sufficientin some cases to measure a single index among the J1-J157 indexes, seefor instance Tables XVIII (J70), XIX (J8), XXI (J74), XXI (J54) and XXV(J42). In some other cases, it is sufficient to measure only two indexesamong the J1-J157 indexes, see for instance Tables XX (J42 and J43),XXIII (J92 and J93) and XXIV (J26 and J28).

In practice, in step (3°) it is recommended to measure at least 8indexes J, advantageously at least 10 indexes J and preferably at least15 indexes J among the J1-J157 indexes.

According to a particular mode for carrying out the method of theinvention, it is recommended to measure at least 8 indexes J,advantageously at least 10 indexes J and preferably at least 15 indexesJ among the J1-J24 indexes.

As a variant, at least one portion of the J1-J24 indexes can be replacedby scores of functions involved in the symptomatology and/or pathologyof the human being to be studied, thoses scores being illustrated by anindex from J25 to J157 or by one or several groups of indexes among theJ25-J157 indexes. Those scores can be used in diagnosing illness orestablished incidents, during establishment or even evaluation ofpotential risk at every stage (in French: “risque encouru à toustermes”).

Said scores of functions involved in the symptomatology and/or pathologyare for instance, but by no way limitative, scores of pregnancy,menstruation, cardiovascularity, thrombosis, Alzheimer's disease,atherosclerosis, cancer, sudden death risk. The sudden death riskcomprises in particular infarct risk, aneurism risk, anaphylactia risk.Cancer risk comprises the one of disease in a general manner, as well asthe one of its localization, in particular brain, colon, prostate glandand breast cancers.

The indexes concerned with the score of menstruation are indicated inExample 1 hereinafter. Thoses related to the score of ovulation aregiven in Example 2 below.

Where other health conditions and/or syndromes are concerned, theindexes to be analyzed according to the invention are the followingones:

-   -   for somatotropic condition (growth and antigrowth): J6, J8, J36,        J37, J38, J39, J54, J67, J74, J82, J85, J319 and J120;    -   for thyroid condition: J2, J4, J16, J39, J68, J72, J74, J81,        J93, J103, J121, J128 and J129;    -   for adaptation syndrome and suprarenal condition: J3, J14, J15,        J26, J27, J28, J29, J34, J39, J68, J69, J70, J87, J88, J94, J95,        J96 and J102;    -   for nuclear growth (to be used in case of carcinogenesis): J1,        J5, J30, J35, J41, J42, J43, J45, J46, J47, J48, J49, J50, J51,        J53, J56, J57, J59, J60, J91, J92, J97, J101 and J141;    -   for general metabolic activity condition: J7, J8, J25, J33, J34,        J40, J44, J45, J61 and J98; and,    -   for rhabdomyolisis risk (i.e. risk of muscular wasting): J22,        J34, J54, J95, J98 and J155.

As a further variant, in step (4°), the comparison of the obtainedindexes with those resulting from median values of parameters for humanbeings recognized as healthy, who are in particular at an idealequilibrium state. Those median values are advantageously determined ona pool of healthy (male or female) subjects according to steps (2°) and(3°) of the method of this invention. In some cases said median valuesare depending upon gender.

For working this invention, five levels of function measures aredistinguished:

-   -   Level 1: functional state detection,    -   Level 2: complete functional state,    -   Level 3: specialized functional conditions (for instance liver,        hypophysis or thyroid, as well as hydratation, muscular        activity),    -   Level 4: examinations per illnesses or syndromes (in particular        thrombosis, Alzheimer's disease, multiple sclerosis, menopause,        osteoporosis, ageing, cardiovascular diseases, effort (sport,        army), psychiatric diseases, cancer, cholesterol),    -   Level 5: indexes of specialists (in particular neurology,        cardiology, cancerology).

The method provided by this invention allows diagnosing and evaluatingthe dynamic biological state of a patient (or a healthy subject) fromthe structure point of view, from the reciprocal interactions (orfunctionings) point of view, and from the point of view of theirevolutions with the passing of time, with the aim of (i) correctingestablished defects, (ii) possibly preventing foreseeable defects, withrespect to the biological state which has been determined in itselements and their reciprocal interactions, from cell to organic level.

In practice, one looks for at least one abnormality at the level of atleast one index J (in particular among J1-J24 or J1-J157), thendepending on this abnormality one studies the indexes which are linkedto or implied by the above cited symptomatology, pathology and/orscores. After that, from the results thus obtained, one determines whatshould be done to cure this abnormality or to prevent risks, illnessesor pathologies linked to or resulting from the foreseeable evolution ofthe patient state.

Each index J of the invention is used to quantify a function or aninteraction. The indexes concerned with a same pathology or score allowevaluating in fine the efficiency or effectiveness of a functionvis-à-vis the metabolic or tissular needs required by the organism. Withall the concerned indexes, the practioner has a precise image of thefunctionality, system by system, and of the real level of the activityof each system.

Thus the method according to the invention provides a specific study ofthe activity level of each function separately or taken in their globalor punctual, general or local interactions. Said method consequentlyallows to determine or to appreciate pathological tendencies of theorganism, the evolution of a given pathology with the passing of timeand the degree of said pathology.

Therefore, said method gives an evaluation of the dynamic biologicalstate of a patient to be tested and provides a profitable help indiagnosing.

In step (1°), a blood sample taken from the patient to be tested isused. Optionally, said blood sample can be added with an anticoagulantagent, such as (preferably) heparin or (possibly) hirudin.

In step (2°), parameters are measured according to classical techniques,and the results thus obtained are given in units or subunits, which areusual in the art. If the same units were not used for given parameters,the values of indexes J, resulting from those parameters in step (3°),could not be compared in step (4°).

Enzymes are measured according to techniques of biological activityknown per se and the results are expressed in international units (IU),in particular as IU/L or IU/mL:

-   -   LDH and CPK are measured according to their global activity and,        optionally, can be isolated according to a method known per se        (for instance by electrophoresis);    -   alkaline phosphatases are also measured according to their        global activity and after can be isolated according to a method        known per se for performing supplemental researches;    -   transaminases are measured according to their specific        activities (in particular their hepatic and muscular ones);    -   γ-glutamyl transpeptidases are measured according to their        global activity.

Among the enzymes, the PAP ones are the sole to be expressed in aweight/volume ratio, namely in ng/L.

Oligoelemnts (K, Na and Cl) are measured according to common techniquesof dosage, and the results are expressed in milliequivalent/L.

Osteocalcin is generally determined according to a RIA method and theresults are expressed in ng/L.

Hemoglobin is measured according to common techniques and the resultsare expressed in g/L.

Red blood cells numeration is performed by direct or automated countingand the results are given in thousands/mL.

Leukocytes numeration is performed by direct or automated counting andthe results are given in real number/mL.

Platelets numeration is performed by direct or automated counting andthe results are given in thousands/mL.

Leukocytes formula is made by direct or automated counting and theresults are given in a percentage of the total number of leukocytes.

Sedimentation rate is made by direct or automated measure and theresults are expressed in hourly (ESR₁) or bihourly (ESR₂) mm.

Thyroid-stimulating hormone (TSH) is measured by a RIA method and theresults are expressed in μIU/L.

Total cholesterol and HLD-cholesterol are measured according to commontechnique of dosage and the results are expressed in g/L.

Tissue markers, used as tissular parameters are determined according toa technique known per se (in particular by RIA) and the results areexpressed in ng/L.

Thyroid hormones (FT3 and FT4) are measured by a RIA or EIA techniqueand the results are expressed in ng/L.

For information, here is the signification of the indexes of thisinvention.

-   J1 A/O the so-called genital ratio index expresses tissular    androgenic activity relative to estrogenic activity,-   J2 the so-called genital-thyroid ratio index (G/T) expresses gonadic    activity relative to thyroid activity; in addition, when it    increases it bears witness to an efficient thyroid activity, and    when it decreases to a rising TSH activity, whatever the absolute    level of the thyroid activity,-   J3 the so-called adaptation index expresses ACTH activity in its    adaptative function relative to FSH activity,-   J4 the so-called thyroid index expresses the metabolic activity of    the thyroid,-   J5 the so-called estrogenic index expresses estrogenic    endocrinometabolic activity,-   J6 the so-called growth index expresses growth hormone metabolic    activity,-   J7 the so-called “turnover” index expresses the speed of tissular    renewal: when it increases it shows a slowdown of this renewal,    conversely when it decreases it shows its acceleration,-   J8 the fibrosis index expresses the fibrotic activity of the    organism; this activity ranges from the mere isolation of a tissue    or organ to the sclerotic degeneration of an organic or tissular    group,-   J9 the index of thyroid involvement expresses the share of the    relative responsibility of the thyrotropic axis in the pathogenicity    of the organism,-   J10 the so-called index of follicular involvement expresses the    share of the relative responsibility of the gonadotropic axis in the    pathogenicity of the organism,-   J11 the so-called index of metabolic-hypothalamic involvement    expresses the share of the relative metabolic responsibility of the    thyrosomatotropic axis in the so-called pathogenicity of the    organism,-   J12 the so-called pancreatic index expresses the metabolic activity    of tissular nutrition by the exocrine pancreas within the    somatotropic axis,-   J13 the so-called global TRH index of adaptation expresses the    metabolic activity of TRH relative to that aspect of its endocrine    activity concerned with the thyrosomatotropic adaptation function,-   J14 the so-called index of leukocytes mobilization expresses the    adaptative releasing capacity of the reserve leukocytes withheld    within the splanchnic area on the hepatic side,-   J15 the so-called index of platelets mobilization expresses the    adaptative releasing capacity of the reserve platelets withheld    within the splanchnic area on the splenic side,-   J16 the so-called index of thyroid reactivating activity expresses    the level of stimulation of the thyrotropic axis by the locus    ceruleus; by extension, it bears witness to the degree of    maladaptation of the organism,-   J17 the so-called structure: function ratio index expresses the    adaptative stimulation of structural tissular mechanisms relative to    that of functional tissular mechanisms,-   J18 the so-called index of estrogenic fraction #1 expresses the    share of the relative estrogenic endocrinometabolic adaptative    activity,-   J19 the so-called index of estrogenic fraction #2 expresses the    liminal adaptative share of the tissular activity of estrogens,-   J20 the so-called index of metabolic estrogenic fraction expresses    the relative share of estrogenic metabolic activity,-   J21 the so-called index of thyroid mobilization of bone metabolism    expresses the effective relative share of thyroid osteoclastic    activity,-   J22 the so-called index of thyroid mobilization of bone endocrine    metabolism expresses the relative endocrinometabolic share of    thyroid osteoclastic activity,-   J23 the so-called index of relative osteomuscular metabolic activity    expresses the share of the metabolic activity of muscle relative to    that of bone,-   J24 the so-called index of thyroid bone metabolic activity expresses    the relative share of thyroid osteoblastic activity,-   J25 the so-called catabolism/anabolism ratio index expresses the    catabolic activity of the organism relative to its anabolic    activity,-   J26 the so-called index of circulating cortisol expresses the    secretory activity of cortisol by the adrenal cortex and its    excretion during the adaptation syndromes,-   J27 the so-called androgenic index expresses the activity of    androgens of gonadic origin relative to that of androgens of adrenal    origin,-   J28 the so-called adrenal cortex index expresses the level of the    global endocrine activity of the adrenal cortex,-   J29 the so-called index of adrenal cortex permissiveness expresses    the level of permissive activity exerted by the adrenal cortex on    the secretory activity of the other endocrine glands,-   J30 the so-called index of aromatization of estrogens expresses the    share of the aromatizing activity of the adrenal cortex relative to    its other activities,-   J31 the so-called level of catabolism expresses the level of the    catabolic activity of the organism,-   J32 the so-called level of anabolism expresses the level of the    anabolic activity of the organism,-   J33 the so-called level of metabolic activity efficiency expresses    the level of the general efficiency of the organism with regard to    production as well as to distribution,-   J34 the so-called index of bone remodeling expresses the level of    bone remodeling and the extent of bone impairment; it also bears    witness to the general level of the metabolism, and specifically to    its adaptation activity,-   J35 the so-called index of nuclear membrane activity expresses the    level of the metabolic activity of the nucleus relative to that of    the membrane; it also reflects their degree of structural dependence    relative to their degree of adaptative functional dissociation,-   J36 the so-called adjusted growth index expresses the level of    intracellular activity of growth factors,-   J37 the so-called anti-growth index expresses the global level of    activity of anti-growth factors as a whole,-   J38 the so-called somatostatin index expresses the level of activity    of somatostatin; it reflects indirectly the relative level of    activity of the exocrine pancreas,-   J39 the so-called prolactin index expresses the level of activity of    prolactin;    -   it bears witness to the level of stimulation of the general        adaptation syndrome and of its systematized units,-   J40 the so-called level of membrane expansion expresses the level of    metabolic activity of the membrane; it allows its quantitative    evaluation relative to the general structural metabolic activity,-   J41 the so-called level of structural expansion expresses the level    of metabolic activity of the nucleus; it allows its quantitative    evaluation relative to the general structural metabolic activity,-   J42 the so-called apoptosis index expresses the level of apoptosic    activity of the organism as a whole,-   J43 the so-called adjusted apoptosis index expresses the degree of    physiological apoptosic activity of the organism as a whole relative    to apoptosic activity resulting from dysfunctional adaptation,-   J44 the so-called level of membrane fracture expresses the degree of    fragility of the membranes—their risk of rupture,-   J45 the so-called necrosis index expresses the level of cellular    explosion related to a necrotic phenomenon relative to cellular    destruction caused by apoptosis,-   J46 the so-called level of activity of total androgens expresses the    level of activity of the androgens taken as a whole,-   J47 the so-called rate of adrenal cortex androgens expresses the    level of activity of androgens originating from the adrenal cortex,-   J48 the so-called rate of genital androgens expresses the level of    activity of androgens of gonadic origin,-   J49 the so-called progesterone index expresses the level of activity    of progesterone,-   J50 the so-called level of activity of genital estrogens expresses    the level of activity of estrogens of gonadic origin,-   J51 the so-called rate of aromatized estrogens expresses the    relative share of compensatory estrogens obtained through the    aromatization of androgens,-   J52 the so-called adrenal cortex index expresses the level of the    global endocrine activity of the adrenal cortex,-   J53 the so-called folliculin index expresses the level of endocrine    activity of the gonadotropic axis in its specific folliculin    fraction,-   J54 the so-called insulin index expresses the level of functional    endocrinometabolic activity of insulin,-   J55 the so-called demyelinization index expresses the relative    functional adaptative activity of insulin in its chronological    relationship with growth hormone activity,-   J56 the so-called index of DNA fracture expresses the degree of    fragility of the nuclei—their risk of rupture,-   J57 the so-called index of nucleocytoplasmic pathogenicity expresses    the level of pathogenicity of the nucleus through the metabolic    dysregulation that it induces within the cytoplasm, which is    exacerbated by the solidity of the membrane,-   J58 the so-called index of cellular fracture expresses the global    degree of fragility of the cells—their risk of rupture,-   J59 the so-called index of carcinogenesis expresses the potential    level of carcinogenesis of the organism through its    nucleocytoplasmic instability in relation to its inadequacy in    apoptosis,-   J60 the so-called index of comparative carcinogenesis expresses the    level of functional carcinogenesis relative to the level of    pathological apoptosis,-   J61 the so-called index of active cellular permeability expresses    the degree of dynamic trans-membrane permeability,-   J62 the so-called index of adjusted active cellular permeability    expresses the degree of dynamic structural trans-membrane    permeability relative to functional permeability,-   J63 the so-called index of passive cellular permeability expresses    the degree of strictly osmotic trans-membrane permeability,-   J64 the so-called index of active intracellular osmolar gradient    expresses the level of maintenance of intracellular osmolarity,-   J65 the so-called index of adjusted active intracellular osmolar    gradient expresses the level of maintenance of structural    intracellular osmolarity relative to functional intracellular    osmolarity,-   J66 the so-called index of passive intracellular osmolar gradient    expresses the relative level of intracellular osmolarity linked to    strictly osmotic trans-membrane permeability,-   J67 the so-called oxidation-reduction index expresses the final    level of the organism's redox activity: that is, after the oxidative    activity and the reductive reaction have taken place,-   J68 the so-called index of corticoadrenal adaptation/permissiveness    expresses the level of the adaptative activity of the adrenal cortex    relative to its permissive activity,-   J69 the so-called adaptogenic index expresses the relative level of    pineal gland participation in the non-circular reactivating of    adaptation,-   J70 the so-called βMSH/αMSH index (differential hormones stimulating    the melanocytes) expresses the relative contribution to the    stimulation of an integrated adaptation by, respectively, the    programmed loop (long loop—pituitary/periphery) and the intercurrent    added loops (short epiphyseal loop),-   J71 the so-called apoptosis index (B) expresses the level of    apoptosis of the organism as a whole,-   J72 the so-called amylosis index expresses the level of    sollicitation of the amyloid activity of the organism—an activity of    structural protection calling for a ‘bridging’ energy in the face of    a functional over-demand for immediate energy (internal    desynchronization of the somatotropic axis),-   J73 the so-called index of amylosis risk expresses the organism's    relative risk of amyloid degeneration in its present functional    equilibrium,-   J74 the so-called index of insulin resistance expresses the relative    level of functional inhibition of the membrane activity of insulin,    independent of temporary inhibition linked to the general adaptation    syndrome,-   J75 the so-called upstream index #1 expresses the relative part    played by the thyroid, within the thyrotropic axis, in the genesis    and maintenance of the current pathology; by extension, it helps one    to evaluate the role of peripheral as compared to central endocrine    activity in the genesis and maintenance of the current pathology,-   J76 the so-called upstream index #2 expresses the relative part    played by the thyroid, within the metabolic equilibrium resulting    from the activity of the follicular fraction of the gonadotropic    axis, in the genesis and maintenance of the current pathology; by    extension, it helps one to evaluate the role of peripheral    endocrinometabolic activity as compared to axial centripetal    endocrine activity in the genesis and maintenance of the current    pathology,-   J77 the so-called upstream index #3 expresses the relative metabolic    part played by the thyroid, through the compensatory activity of the    thyrosomatotropic axis, in the genesis and maintenance of the    current pathology; by extension, it helps one to evaluate the role    of peripheral metabolic as compared to central metabolic activity in    the genesis and maintenance of the current pathology,-   J78 the so-called global upstream index #1 expresses the part played    by the follicular fraction of the gonadotropic axis relative to the    part played by the thyrometabolic fraction of the thyrotropic axis    in the genesis and maintenance of the current pathology; by    extension, it helps one to evaluate the role of centripetal axial    endocrine activity as compared to central endocrine activity,-   J79 the so-called global upstream index #2 expresses the part played    by the compensatory activity of the thyrosomatotropic axis relative    to the activity of the thyrometabolic fraction of the thyrotropic    axis in the genesis and maintenance of the current pathology; by    extension, it helps one to evaluate the role of central metabolic as    compared to central endocrine activity,-   J80 the so-called global upstream index #3 expresses the share of    the compensatory activity of the thyrosomatotropic axis relative to    the activity of the follicular fraction of the gonadotropic axis; by    extension, it helps one to evaluate the role of central metabolic    activity as compared to centripetal axial endocrine activity,-   J81 the so-called index of thyroid output #1 expresses thyroid    metabolic activity relative to the level of hypophyseal stimulation;    by extension, it helps one to evaluate the threshold of the    thyroid's response when stimulated by the pituitary gland,-   J82 the so-called index of free radicals expresses the global    circulating rate of free radicals,-   J83 the so-called adjusted index of free radicals expresses the    residual circulating rate of free radicals,-   J84 the so-called comparative index of free radicals expresses the    rate of the free radicals with a structural purpose relative to the    rate of the free radicals with a functional purpose,-   J85 the so-called index of free radical nocivity expresses the rate    of toxic free radicals relative to the rate of biologically    justified free radicals,-   J86 the so-called adjusted apoptosis index (B) expresses the rate of    anticipated apoptosis relative to the physiological rate of    apoptosis,-   J87 the so-called index of active histamine expresses the level of    active histamine in circulation,-   J88 the so-called index of potential histamine expresses the level    of histamine carriers, both fixed and mobile,-   J89 the so-called TRH index expresses the relative share of TRH's    vertical activity within the thyrotropic axis,-   J90 the so-called index of relative intrathyroid TRH activity    expresses the relative role of TRH in the endocrine activity of the    thyroid,-   J91 the so-called index of carcinogenic expansion expresses the    degree and rapidity of anarchic tissue development within the    organism; by extension, it allows one to track the progression of a    known tumor, the degree and speed of its development,-   J92 the so-called index of cancer potential expresses the relative    level of the endocrinometabolic factors favourable to dysplasia,-   J93 the so-called adenosis index expresses the relative level of the    factors favourable to hyperplasia,-   J94 the so-called ischemia reperfusion index expresses the level of    tissular congestion relative to cellular metabolic activity,-   J95 the so-called thrombogenic index expresses the risk of    atherogenic transformation in the arterial walls; by extension, it    allows one to evaluate the risk of thrombosis in the lumen,-   J96 the so-called thrombotic index expresses the risk of thrombus    development; by extension, it allows one to evaluate the level of    blood coagulability,-   J97 the so-called adjusted genital ratio index expresses the basal    level of tissular androgenic activity relative to estrogenic    activity, outside any acute adaptation phenomena,-   J98 the so-called musculotropic index expresses the relative    endocrinometabolic impact on muscle, in relation to the normal    distribution of gonadic effects on muscle and bone,-   J99 the so-called adjusted estrogenic index expresses the    endocrinometabolic activity of the estrogens on the tissues; by    extension, it bears witness to their potential level of specific    activity within the structure of the organism,-   J100 the so-called genital androgeny index expresses the    endocrinometabolic activity of the gonadic androgens on the tissues;    by extension, it bears witness to their potential level of specific    activity within the structure of the organism,-   J101 the so-called comparative genital androgeny index expresses the    metabolic level of activity of the androgens' specific tissular    targets; by extension, it bears witness to the functional level of    activity of the androgens within the structure of the organism,-   J102 the so-called “starter” index expresses the degree of    hepatotropic stimulation by the splanchnic system, relative to    splenotropic stimulation, in response to any kind of aggression,    direct or indirect, on the tissues; by extension, it bears witness    to the functional level of glucagon relative to that of adrenalin    during the activation of the general adaptation syndrome, and    consequently to the respective response threshold of both hormones    to endogenous as well as exogenous stimulation; by extension, it    bears witness to the level of priority of the energometabolic    adaptative response relative to the neuroendocrine response,-   J103 the so-called adjusted index of thyroid reactivating activity    expresses the part played by endogenous factors in the stimulation    of the thyrotropic axis by the locus coeruleus; by extension, it    bears witness to the degree of endogenous maladaptation of the    organism,-   J104 the so-called pro-inflammatory index expresses the dysmetabolic    potential of endogenous thyrotropic maladaptation and of its    correction by cortisol; by extension, it bears witness to the degree    of inflammatory stimulation of the structure in its unit of    adaptability,-   J105 the so-called index of inflammation expresses the actual level    of inflammatory activity of the organism, of endogenous origin, in    its present functional state; by extension, it bears witness to the    threshold and to the gradient of the inflammatory reactivity of the    individual,-   J106 the so-called comparative index of inflammation expresses the    degree of inflammation that is fundamental and structural relative    to inflammation that expresses a functional and/or adaptative    adjustment,-   J107 the interleukin 1 index expresses the specific level of    activity of interleukin 1, in its stimulation of growth as well as    in its lymphocytic specificity,-   J108 the dehydroepiandrosterone (DHEA) index expresses the level of    DHEA endocrinometabolic activity; by extension, it permits the    evaluation of its level of secretion and the degree of gonadotropic    transformation,-   J109 the serotonin index expresses the level of autacoid and    metabolic activity of peripheral serotonin; by extension, it permits    the evaluation of the level of neurometabolic activity of central    serotonin,-   J110 the so-called adjusted demyelinization index expresses the    relative level of adaptability of the energometabolic response of    insulin in its chronological relationship with the endocrine    response of growth hormone,-   J111 the so-called expansiveness index #1 expresses the potential    level of cellular growth in its function of structural metabolic    adaptation,-   J112 the so-called expansiveness index #2 expresses the degree of    risk of anarchic cellular development related to the adaptative    modalities of the metabolism insofar as these have consequences with    structural implications,-   J113 the so-called global expansiveness index expresses the actual    share of retained cellular expansion relative to the degree of    destruction of pathological cells,-   J114 the so-called ACTH index expresses the level of organometabolic    activity of corticotropin,-   J115 the so-called PTH index expresses the level of    endocrinometabolic activity of parathormone,-   J116 the so-called index of gonadotropic output expresses the    endocrine activity of the gonadic estrogens relative to the level of    stimulation by the pituitary; by extension, it helps one to evaluate    the threshold of estrogenic response to hypophyseal stimulation; by    extension, it helps one to evaluate the part that functional gonadic    deficiency plays in the reactional activity of the hypophyseal    gonadotrophins,-   J117 the so-called index of pelvic congestion expresses the level of    physiological pelvic congestion relative to pathological congestion,-   J118 the so-called index of splanchnic congestion expresses the    relative level of active congestion of the splanchnic reservoir; by    extension, it situates the relative level of adapted congestion and    of its reactive reduction,-   J119 the so-called growth score index expresses the balanced    resultant of the growth and anti-growth factors; by extension, it    evaluates actual growth, organic as well as functional; by    extension, it evaluates the potential for development of healthy or    sick organs, as a result of factors structural, functional or    adaptative (structural or functional adaptation),-   J120 the so-called GH growth score index expresses the level that    results from the endocrinometabolic activity of growth hormone; by    extension, it evaluates the role played by the somatotropic axis in    the general adaptation syndrome; by extension, it evaluates the role    played by the somatotropic axis in the summoning and distribution of    structural as well as of functional energy; by extension, it    evaluates the degree to which growth hormone is responsible for the    distribution of metabolic energy, whether in the sense of    architecture, evolution or maintenance, or whether it be functional,    chronological or adaptative,-   J121 the so-called TRH/TSH ratio index expresses the level of TRH    activity on the tissues—structural as well as adaptative—relative to    TSH activity; by extension, it evaluates the level of congestion,    compared to that of hyperplasia, in the process of anabolic    adaptation; by extension, it evaluates the share of nutrition    relative to metabolic output; by extension, it evaluates the share    of neuroendocrine adaptation relative to organometabolic adaptation;    by extension, it evaluates the share of potential elaboration    relative to structural achievement; by extension, it evaluates the    share of the imaginary relative to material realization,-   J122 the so-called index of thyroid efficiency expresses the    activity of the thyroid on the tissues as part of its structural    activity,-   J123 the so-called index of relative thyroid efficiency expresses    the tissular metabolic activity of the thyroid relative to its    actual metabolic activity,-   J124 the so-called index of oxidation expresses the part played    exclusively by the oxidation phase in the phenomenon of    oxidation-reduction; by extension, it helps one to evaluate the    level of cellular respiration,-   J125 the so-called index of reduction expresses the part played    exclusively by the reduction phase in the phenomenon of    oxidation-reduction; by extension, it helps one to evaluate the    level of the organism's antioxidant activity,-   J126 the so-called pro-amyloid index expresses the level of    intracellular hypometabolism; by extension, it evaluates the degree    of cellular respiratory insufficiency; by extension, it evaluates    the degree of cellular nutritional insufficiency,-   J127 the so-called index of amyloid risk expresses the risk of    amyloid degeneration of the organism; by extension, it evaluates the    risk of intracerebral degenerative disease, and particularly of    Parkinson's and Alzheimer's disease,-   J128 the so-called index of thyroid output #2 expresses the tissular    activity of the thyroid relative to the level of specific    stimulation by the hypophyseal trophic hormones; by extension, it    helps one to evaluate the thyroid's relative threshold of    participation in cellular distribution,-   J129 the so-called comparative index of thyroid output expresses the    tissular activity of the thyroid relative to total metabolic    activity; by extension, it helps one to evaluate the relative    threshold of stimulation of the orientation activity of cellular    distribution by the thyrotropic axis,-   J130 the so-called index of estrogenic fraction #3 expresses the    relative part played by the estrogens in endocrine tissular    regulation within the gonadic apparatus,-   J131 the so-called index of estrogenic fraction #4 expresses the    extra adaptative endocrinometabolic cost incurred in the tissular    activity of the estrogens,-   J132 the so-called index of estrogenic fraction #5 expresses the    relative share of the estrogens devoted to organotissular growth,-   J133 the so-called general index of estrogenic fraction expresses    the global share, structural as well as adaptative, of the estrogens    devoted to organotissular growth,-   J134 the so-called index of estrogenic fraction #6 expresses the    endocrinometabolic activity of estrogens devoted to a structural    structurofunctional mode of adaptation; by extension, it evaluates    the level of gonadothyroid solidarity within the various    adaptability units, and helps one to evaluate to what degree    estrogenic demand is responsible for thyroid dysfunction,-   J135 the so-called index of estrogenic fraction #7 expresses the    extra adaptative endocrinometabolic cost of the activity of    estrogens devoted to a structural structurofunctional mode of    adaptation; by extension, it evaluates the endocrine cost of    gonadothyroid solidarity within the various adaptability units, and    it thus the reinjected cost of estrogenic demand in thyroid    dysfunction,-   J136 the so-called index of estrogenic fraction #8 expresses    estrogenic endocrine activity within the gonadotropic adaptability    unit; by extension, it evaluates the level of tissular    anabolic/catabolic equilibrium and of tissular bone-remodeling    equilibrium,-   J137 the so-called general quantitative estrogenic index expresses    the final quantitative activity of the estrogens at the cellular and    tissular level; by extension, it evaluates the proteic yield, and    hence the level of nuclear activity relative to cellular and then to    tissular activity,-   J138 the so-called index of specific estrogenic fraction expresses    the musculotropic activity of the estrogens; by extension, it    evaluates the level of estrogenic endocrine activity as part of the    gonadic activity,-   J139 the so-called comparative estrogenic index #1 expresses the    share of estrogenic activity devoted to organotissular growth    relative to total endocrinometabolic activity,-   J140 the so-called comparative estrogenic index #2 expresses the    share of estrogenic activity devoted to organotissular growth    relative to total endocrinometabolic tissular activity,-   J141 the so-called global comparative estrogenic index expresses the    share of estrogenic activity devoted to organotissular    growth—whether it be an adaptative growth of restoration (as well as    of function) or a basal structural growth or a growth of    adaptability,-   J142 the so-called index of somatotropic estrogenic output expresses    the organotissular growth activity of the peripheral estrogens    relative to the global activity of pituitary FSH,-   J143 the so-called index of quantitative organotissular estrogenic    output expresses the organotissular activity of the peripheral    estrogens relative to the global activity of pituitary FSH,-   J144 the so-called FSH index #1 expresses the organometabolic    activity of pituitary follicle-stimulating hormone,-   J145 the so-called LH index#1 expresses the endocrinometabolic    activity of pituitary luteinizing hormone,-   J146 the so-called FSH index #2 expresses the endocrinometabolic    activity of pituitary follicle-stimulating hormone,-   J147 the so-called LH index #2 expresses the organometabolic    activity of pituitary luteinizing hormone,-   J148 the so-called index of progesterone output expresses the    gonadic endocrine activity of progesterone relative to that of    estrogen,-   J149 the so-called ketonic index expresses the level of prevalence    of glucagon over the adrenal-insulinic reaction; by extension, it    allows one to evaluate the role played, in the management of    glucide-derived energy, by the ketonic route relative to the    insulinic and to the cortico-adrenergic route,-   J150 the so-called index of total subliminal TRH expresses the    threshold of reactivity of TRH in its thyrotropic endocrine activity    (hypophyseal and thyroid), as well as in its thyrosomatotropic    metabolic activity,-   J151 the so-called index of active carcinogenesis expresses the    actual carcinogenetic level of the organism, retained and related to    the degree of destruction of pathological cells (through apoptosis    or necrosis),-   J152 the so-called comparative index of active carcinogenesis    expresses the actual functional level of the carcinogenesis within    the organism, retained and related to the degree of destruction of    pathological cells (through apoptosis or necrosis),-   J153 the so-called gonadothyrotropic index expresses the part played    by the gonads in the appeal to and the response by the thyroid, both    metabolic and endocrine, in the functional adaptation of structure,-   J154 the so-called index of global tissular estrogenic fraction    expresses the relative share of estrogenic activity devoted entirely    to the tissues.

The software product according to the invention can be used with acomputer, either an analog one or a digital one. In practice, it isloaded either directly in the computer memory or indirectly by means ofa software interface or of an intermediary module, the aforesaid memorybeing (preferably) internal or auxiliary.

Whatever the operating mode, the configuration, the structure or theoperating system of the computer, it is advisable to store up thesoftware product on a computer readable medium. It comprises computerreadable software means which are needed to execute steps (3°) and (4°)of the method according to the invention.

In practice, said software product comprises:

-   -   (A) a form field for entering (i) the patient's name or        code, (ii) his age, and (iii) his sex, on the one hand, and any        known treatment followed by said patient formerly or at the        present time, on the other hand;    -   (B) a form field for entering (iv) one or several hematic        parameters measured in vitro in the patient's blood and (v) the        date of the measures;    -   (C) a field including all the indexes from J1 to J157, (vii)        their calculation mode and (viii) their median values determined        from human beings who are recognized as healthy subjects;    -   (D) a command for (ix) the calculation of one index J, of        several indexes J or the totality of indexes from the hematic        parameters of said field (B) obtained from the blood of the        patient to be tested, and (x) for the comparison of the obtained        value for at least one of said indexes J with its median value        of field (C); and,    -   (E) means for classifying, visualizing, editing and/or printing        the obtained result by implementing command (D) starting from        fields (A), (B), and (C).

Field (A) is designed for the input of the data that are essential andnecessary to identify the patient (his name or his code number, hisage), and of the data allowing the improvement of the comparisonanalysis according to step (4°) of the method of the invention (followedtreatment).

It is recommended to note the blood sampling date and (if it isdifferent) the determination date of the parameter(s) of step (2°).

Each median value of an index J comprises an interval of normal valuespreviously reckoned among adults who are healthy subjects.

Moreover, it is advisable to include in the software product accordingto the invention an instruction for the reckoning and flagging up of anyabnormality consisting of a value of an index J which stands away fromthe median value or from its interval.

Other advantages or characteristics of the invention will be betterunderstood when reading the following implemented examples. Of course,these examples are by no means limitative, but they are given asillustration purpose.

In these examples, when the determination (“typing”) of one or severalparameters of step (2°) is stated at times T₀, T₁, T₂, T₃, etc., it isproper to recall that the time intervals T₁-T₀, T₂-T₁, T₃-T₂, etc.between two determinations, depend on the patient and on the evolutionof his pathology; in other words these time intervals are variable, onthe average they last 2, 3, 4, and even 6 months.

EXAMPLE 1 Menstruation Score

The menstruation score comprises, among others:

A very noticeable increase (see Table I) in:

-   -   the necrosis index (J45)    -   the oxidation-reduction index (J67)    -   the index of oxidation (J124)    -   the index of free radicals (J82)    -   the thrombotic index (J96), and

the level of catabolism (J31): TABLE I MENSTRUATION SCORE INCREASE OFJ45, J67, J124, J82, J96 et J31 Date Control 99/10/02 00/09/09 99/09/0700/6/19 99/09/21 97/09/09 (normal Day of the cycle interval) 3 d/30 d 1d/29 d 3 d/28 d 1 d/28 d 2 d 3 d/32 d Mini Maxi Name D. Murielle D.Murielle G. Véronique G. Véronique M. Danila D. Cécile 2.5 6 J45  22.9724.21 109.82 100.63 9.6 77.27 Date 99/10/02 00/09/09 99/09/07 00/6/1999/09/21 97/09/09 Day of the cycle Control 3 d/30 d 1 d/29 d 3d /28 d 1d/28 d 2 d 3 d/32 d Mini Maxi Name D. Murielle D. Murielle G. VéroniqueG. Véronique M. Danila D. Cécile 0.7 2 J67  20257 7720 29391 72334 12154707 1.44 81 J124 11309 5917.86 1965 2784 1384.76 817.01 0.25 0.6 J82 842.49 382.92 2205 7336 94.39 408.16 4 8 J96  24.53 25.25 10.26 16.603.50 1.05 1.3 1.6 J31  0.75 0.77 2.64 1.93 0.73 1.35

And a very noticeable decrease (see Table II) for:

-   -   the index of reduction (J125)    -   the fibrosis index (J8)    -   the amylosis index (J72)

the level of anabolism (J32), and the prolactin index (J39). TABLE IIMENSTRUATION SCORE, INDEXES DECREASE J125, J8, J72, J32 and J39 Date99/10/02 00/09/09 99/09/07 00/6/19 99/09/21 97/09/09 Day of the cycleControl 3 d/30 d 1 d/29 d 3 d/28 d 1 d/28 d 2 d 3 d/32 d Mini Maxi NameD. Murielle D. Murielle G. Véronique G. Véronique M. Danila D. Cécile0.72 116 J125 0.56 0.77 0.07 0.04 1.14 0.17 6 8 J8  0.28 0.43 1.52 0.480.68 3.01 10 17 J72  0.56 0.66 1.15 0.26 0.35 0.11 0.65 0.8 J32  0.220.23 1.48 0.77 0.21 0.48 0.8 1.2 J39  0.20 0.20 0.24 0.10 0.13 0.05

EXAMPLE 2 Ovulation Score

The ovulation score comprises among others:

A very noticeable increase (see Table III) for:

-   -   the prolactin index (J39)    -   the index of circulating cortisol (J26)    -   all the tissular indexes of estrogens (J19, J134, J135)    -   the index of reduction (J125)    -   the fibrosis index (J8)    -   the amylosis index (J72), and    -   the level of anabolism (J32);        for the same sample of observations, this increase is shown in        Table III by the ratio (O/M) of the basic values during the        cycle (O) relative to the values during or around menstruation        (M); and

A very noticeable decrease (see Table IV) for:

the indexes of metabolic activity of estrogens (J20 et J138). TABLE IIIOVULATION SCORE, INDEXES INCREASE Ratio O/M O/M O/M O/M Name Index D.Murielle G. Véronique M. Danila D. Cécile J39 5.03 1.62 1.70 10.75 J261.26 2.18 2.29 0.52 J134 2.67 2.40 1.08 1.06 J135 1.29 1.22 1.03 1.54J19 1.23 1.07 1.02 1.47 J125 57.00 1000.85 24.31 457.51 J8 21.93 4.933.87 3.17 J72 8.82 13.06 1.58 30.73 J32 1.41 0.06 0.69 0.36

TABLE IV OVULATION SCORE, INDEXES DECREASE Ratio O/M O/M O/M O/M NameIndex D. Murielle G. Véronique M. Danila D. Cécile J138 0.32 2.48 1.472.16 J20 0.42 0.59 0.85 1.22

EXAMPLE 3 Seasonal Syndrome

The pre-seasonal autumn syndrome is analyzed below. It bears witness tothe metabolic summoning (i.e. implementing or mobilization of thebiological potential involved) essential for winter structuro-functionalequilibrium. It is an adaptability period which implies putting in placethe general adaptative crossroads, immediate mobilization of thethyrosomatotropic axis and preparation of the functional increase of thegonadotropic axis. It is expressed by the pre-autumn score. Itcomprises, among others:

A clear increase of:

-   -   on the adaptative level (see Table V):        -   the “starter” index (J102)        -   the index of potential histamine (J88)        -   the prolactine index (J39)        -   the index of active histamine (J87)        -   the index of circulating cortisol (J26)

the index of corticoadrenal adaptation/permissiveness (J68); TABLE VControl Mini Maxi Indexes Obtained data 0.85 1.15 J102 1.30 6 12 J88630.70 0.8 1.2 J39 1.40 20 60 J87 168.87 3 7 J26 7.51 1 3 J68 5.09

-   -   on the strictly thyrotropic thyrosomatotropic level (see Table        VI):        -   the index of thyroid reactivating activity (J16)        -   the adjusted index of thyroid reactivating activity (J103)        -   the index of thyroid output #1 (J81)        -   the TRH/TSH ratio index (J121)        -   the adenosis index (J93);

the index of thyroid involvement (J9); TABLE VI Control Mini MaxiIndexes Collected data 0.05 0.25 J16 0.28 0.1 0.5 J103 0.62 2 3 J81 3.100.33 1.70 J121 4.75 10 30 J93 40.98 4 8 J9 27.78

-   -   on the specific thyrosomatotropic level (see Table VII):        -   the amylosis index (J72)        -   the index of amylosis risk (J73)        -   the pro-amyloid index (J126)        -   the index of amyloid risk (J127)        -   the index of insulin resistance (J74)        -   the fibrosis index (J8)        -   the insulin index (J54)

the demyelinization index (J55): TABLE VII Control Mini Maxi IndexesObserved data 10 17 J72 25.22 5 8 J73 30541.88 0.54 145.50 J126 523.800.07 5.56 J127 92.10 0.75 1.25 J74 2.27 6 8 J8 17.87 1.5 5 J54 8.83 5 15J55 23.11

-   -   on the gonadotropic level (see Table VIII):        -   the folliculin index (J53)        -   the index of somatotropic estrogenic output (J142)        -   the level of activity of genital estrogens (J50)        -   the androgenic index (J27)        -   the level of activity of total androgens (J46)        -   the rate of genital androgens (J48)        -   the adjusted estrogenic index (J99)        -   the genital androgeny index (J100)

the comparative genital androgeny index (J101); TABLE VIII Control MiniMaxi Indexes Observed data 0.75 1.25 J53 1.80 2.14 206.25 J142 7369.901.2 2 J27 2.82 0.2 0.25 J46 0.25 0.12 0.17 J48 0.27 0.12 0.16 J50 0.180.2 0.5 J99 −0.65 0.05 0.09 J100 −1.86 0.1 0.3 J101 1.90

-   -   on the metabolic level (see Table IX):        -   the index of active cellular permeability (J61)        -   the index of adjusted active cellular permeability (J62)        -   the index of passive cellular permeability (J63)        -   the index of active intracellular osmolar gradient (J64)        -   the index of adjusted active intracellular osmolar gradient            (J65)        -   the insulin index (J54)        -   the adjusted growth index (J36)        -   the oxidation-reduction index (J67)        -   the index of oxidation (J124)        -   the index of free radicals (J82)        -   the adjusted index of free radicals (J83)        -   the comparative index of free radicals (J84)        -   the index of free radical nocivity (J85)        -   the level of anabolism (J32)        -   the index of pelvic congestion (J117)        -   the index of splanchnic congestion (J118)        -   the serotonin index (J109)        -   the index of insulin resistance (J74)        -   the level of metabolic activity efficiency (J33)

the level of catabolism (J31); TABLE IX Control Mini Maxi IndexesCollected data 6 9 J61 15.38 0.8 1 J62 1.72 4 9 J63 57.33 8 12 J64 81.121 1.5 J65 5.16 1.5 5 J54 8.83 0.06 0.1 J36 0.15 0.7 2 J67 154827.17 1.4481.48 J124 1905.92 0.25 0.6 J82 8913.29 1.8 3.5 J83 8896.86 2 4 J848894.56 2 6 J85 45789.68 0.65 0.8 J32 1.17 0.01 0.19 J117 1.50 0.01 0.16J118 1.62 1.5 7.5 J109 14.50 0.75 1.25 J74 2.27 80 1.40 J33 334 1.3 1.6J31 1.98

-   -   on the pathogenesis level (see Table X):        -   the necrosis index (J45)        -   the level of membrane expansion (J40)        -   the level of membrane fracture (J44)        -   the index of nucleocytoplasmic pathogenicity (J57)        -   the index of carcinogenesis (J59)        -   the index of comparative carcinogenesis (J60)        -   the expansiveness index #1 (J111)        -   the expansiveness index #2 (J112)        -   the level of structural expansion (J41)        -   the index of cancer potential (J92)        -   the index of cellular fracture (J58)        -   the index of pelvic congestion (J117)        -   the index of splanchnic congestion (J118)        -   the pro-inflammatory index (J104)        -   the index of inflammation (J105)        -   the comparative index of inflammation (J106)

the thrombotic index (J96); TABLE X Control Mini Maxi Indexes Observeddata 2.5 6 J45 27.75 0.08 0.16 J40 0.25 1.5 1.9 J44 4.54 0.8 1.5 J571.55 1 3 J59 9.76 1 1.5 J60 2.40 0.06 2 J111 2.11 1 4 J112 4.72 0.040.08 J41 0.09 10 J92 2154166 0.5 1.5 J58 1.69 0.01 0.19 J117 1.50 0.010.16 J118 1.62 0.1 0.4 J104 0.42 0.3 2.5 J105 11.24 0.2 2.5 J106 10.39 48 J96 26.92

A clear decrease (see Table XI) in:

-   -   the turn over index (J7)    -   the catabolism/anabolism ratio index (J25), and a relative        decrease in:

the musculotropic index (J98); TABLE XI Control Mini Maxi IndexesCollected data 40 60 J7 39.3 1.8 3 J25 1.72 0.53 4.72 J98 4.25

In summer, the musculotropic index rises up to 12.87, the ratio ofpre-automn/summer values is therefore much lower than 1; it is equal to0.33.

EXAMPLE 4 Seasonal Score

The pre-seasonal spring syndrome is analyzed below. It bears witness tothe metabolic summoning essential for the summer structuro-functionalequilibrium. It is an adaptability period which implies putting in placethe general adaptation crossroads, immediate mobilization of thethyrosomatotropic axis and preparation of the functional decrease of thegonadotropic axis. It is expressed by the pre-spring score. Itcomprises, among others:

A clear increase in:

-   -   at the adaptative level (see Table XII):        -   the “starter” index (J102)        -   the index of potential histamine (J88)        -   the prolactine index (J39)        -   the index of active histamine (J87)        -   the ACTH index (J114)        -   the DHEA index (J108)        -   the adaptation index (J3)        -   the index of circulating cortisol (J26)

the adrenal cortex index (J28); TABLE XII Control Mini Maxi IndexesObserved data 0.85 1.15 J102 1.32 6 12 J88 −73.91 0.8 1.2 J39 1.40 20 60J87 295.00 0.71 3.00 J114 107.07 5 9 J108 132.24 0.25 0.5 J3 0.58 3 7J26 7.32 2.7 3.3 J28 3.59

-   -   at the strictly thyrotropic thyrosomatotropic level (see Table        XIII):        -   the index of thyroid involvement (J9);        -   the index of thyroid reactivating activity (J16)        -   the adjusted index of thyroid reactivating activity (J103)        -   the TRH/TSH ratio index (J121)

the adenosis index (J93); TABLE XIII Control Mini Maxi Indexes Collecteddata 0.05 0.25 J16 0.27 0.1 0.5 J103 0.65 0.33 1.70 J121 5.69 4 8 J939.00 10 30 J93 63.35

-   -   at the specific thyrosomatotropic level (see Table XIV):        -   the amylosis index (J72)        -   the index of insulin resistance (J74)        -   the level of membrane expansion (J40)        -   the insulin index (J54)        -   the fibrosis index (J8)        -   the adjusted growth index (J36)        -   the level of structural expansion (J41)        -   the prolactin index (J39)

the interleukin 1 index (J107); TABLE XIV Control Mini Maxi IndexObserved data 10 17 J72 29.77 0.75 1.25 J74 1.41 0.08 0.16 J40 0.17 1.55 J54 4.92 6 8 J8 13.02 0.06 0.1 J36 0.13 0.04 0.08 J41 0.06 0.8 1.2 J391.40 0.1 0.16 J107 0.20

-   -   at the gonadotropic level (see Table XV):        -   the folliculin index (J53)        -   the index of somatotropic estrogenic output (J142)        -   the FSH index #1 (J144)        -   the LH index #1 (J145)        -   the genital androgeny index (J100)        -   the comparative genital androgeny index (J101)        -   the androgenic index (J27)        -   the level of activity of total androgens (J46)        -   the rate of genital androgens (J48)

the level of activity of genital estrogens (J50) TABLEAU XV Control MaxiIndexes Observed data 1.25 J53 1.33 206.25 J142 633.62 12.00 J144 76.386.00 J145 61.44 0.09 J100 0.35 0.3 J101 0.88 2 J27 2.76 0.25 J46 0.300.17 J48 0.21 0.16 J50 0.19

-   -   at the metabolic level (see Table XVI):        -   the index of active cellular permeability (J61)        -   the index of adjusted active cellular permeability (J62)        -   the index of passive cellular permeability (J63)        -   the index of active intracellular osmolar gradient (J64)        -   the index of passive intracellular osmolar gradient (J66)        -   the insulin index (J54)        -   the adjusted growth index (J36)        -   the level of anabolism (J32)        -   the oxidation-reduction index (J67)        -   the index of oxidation (J124)        -   the index of free radicals (J82)        -   the adjusted index of free radicals (J83)        -   the comparative index of free radicals (J84)        -   the index of free radical nocivity (J85)        -   the level of catabolism (J31);    -   the serotonin index (J109)        -   the index of insulin resistance (J74)        -   the prolactin index (J39)        -   the level of metabolic activity efficiency (J33)

the index of reduction (J125); TABLE XVI Control Mini Maxi IndexesObserved data 6 9 J61 16.40 0.8 1 J62 4.31 4 9 J63 20.37 8 12 J64 10.481 3.3 J66 3.92 1.5 5 J54 4.92 0.06 0.1 J36 0.13 0.65 0.8 J32 0.89 0.7 2J67 2515.12 1.44 81.5 J124 233.09 0.25 0.6 J82 468.02 1.8 3.5 J83 464.862 4 J84 466.58 1.70 6.00 J85 100039.73 1.3 1.6 J31 1.68 1.5 7.5 J10916.83 0.75 1.25 J74 1.41 0.8 1.2 J39 1.40 80 140 J33 114.25 0.7 116 J125271.91

-   -   at the pathogenesis level (see Table XVII):        -   the index of free radical nocivity (J85)        -   the necrosis index (J45)        -   the oxidation-reduction index (J67)        -   the index of cellular fracture (J58)        -   the level of membrane expansion (J40)        -   the level of membrane fracture (J44)        -   the fibrosis index (J8)        -   the index of cancer potential (J92)        -   the index of carcinogenesis (J59)        -   the level of structural expansion (J41)        -   the index of comparative carcinogenesis (J60)        -   the index of DNA fracture (J56)        -   the expansiveness index #1 (J111)        -   the expansiveness index #2 (J112)        -   the index of nucleocytoplasmic pathogenicity (J57)        -   the index of carcinogenic expansion (J91)        -   the adenosis index (J93)        -   the amylosis index (J72)        -   the index of amylosis risk (J73)        -   the index of potential histamine (J88)        -   the pro-inflammatory index (J104)        -   the index of inflammation (J105)        -   the comparative index of inflammation (J106)        -   the index of splanchnic congestion (J118)        -   the thrombotic index (J96)        -   the pro-amyloid index (J126)        -   the index of amyloid risk (J127);

And a clear decrease in:

the βMSH/αMSH index (J70) (see Table XVIII) TABLE XVII Control Mini MaxiIndexes Observed data 0.08 0.16 J40 0.32 0.04 0.08 J41 0.18 2.5 6 J459.69 6 8 J8 13.02 0.5 1.5 J56 1.62 0.8 1.5 J57 3.43 1.5 1.9 J44 3.96 0.51.5 J58 2.12 1 3 J59 43.36 1 1.5 J60 2.49 0.7 2 J67 2515.12 10 17 J7229.77 5 8 J73 45178.57 1.70 6.00 J85 100039.73 6 12 J88 −73.91 0.3 1 J912.70 6 10 J92 6436.12 10 30 J93 63.35 5 8 J96 26.92 0.1 0.4 J104 0.590.3 2.5 J105 5.83 0.2 2.5 J106 5.38 0.06 2 J111 2.95 1 4 J112 8.32 0.010.19 J117 2.30 0.01 0.16 J118 2.06 0.5 146 J126 423.03 0.1 6 J127 14.45

TABLE XVIII Control Mini Maxi Indexes Collected data 6 8 J70 5.04

EXAMPLE 5 Characteristic Variations of Specific Indexes

One notices, among others, a characteristic increase in the fibrosisindex (J8) during evolutionary phases, toward cirrhosis, of hepaticdegenerative affections, particularly during viral hepatitis andevolutionary phases of pulmonary fibrosis during spurts of chronicbronchitis.

Table XIX below shows the regressive evolution of the fibrosis index(J8), under the influence of endobiogenic treatment, with a patientsuffering from hepatitis C, between time T₀ and time T₃. TABLE XIXControl Observed data Mini Maxi Indice T₀ T₁ T₂ T₃ 6 8 J8 14.5 14.3 6.93.8

One notices an important increase in the apoptosis index (J42) duringevolutionary spurts and viral replication of the main viral diseasessuch as AIDS, viral hepatitis, influenza, and during characteristic fitsof radical overactivity.

Table XX below shows the regressive evolution of the apoptosis indexes(J42 and J43) under the influence of a triple therapy treatment with apatient suffering from AIDS, at time T₀, T₁, T₂, T₃, T₄ and T₅. TABLE XXControl Observed data Mini Maxi Indexes T₀ T₁ T₂ T₃ T₄ T₅ 0.3 0.7 J426638 5827 623049 364647 525 91 5 8 J43 3723 2194 20229 3897 412 187

One also notices an increase in the index of insulin resistance (J74)during setting in phases and evolutionary phases ofnon-insulin-dependent diabetes.

In Table XXI below, one has put down the regressive evolution of theindex of insulin resistance (J74) under the influence of endobiogenictreatment and diet with obese and pre-diabetic patients, at time T₀, T₁,T₂ and T₃. TABLE XXI Control Observed data Patient Mini Maxi Index T₀ T₁T₂ T₃ 1 0.75 1.25 J74 3.15 1.69 0.47 0.37 2 0.75 1.25 J74 30.15 8.512.41 3 0.75 1.25 J74 12.89 9.80 1.05 0.95 4 0.75 1.25 J74 34.7 21.880.30 0.19 5 0.75 1.25 J74 3061 143 6 0.75 1.25 J74 1.83 1.04 7 0.75 1.25J74 23.9 3.86 0.44 0.16 8 0.75 1.25 J74 9.12 3.58 0.81

One also notices an increase of the insulin index (J54) during settingin phases, as well as during chronic phases of obesity (see Table XXII).TABLE XXII Observed data Patient Control Index T₀ T₁ T₂ T₃ 9 1.5 5 J544.56 51.16 10 1.5 5 J54 49.07 11 1.5 5 J54 3.09 7.88 9.22 90.81 5 J544.25 9.96

One also notices an increase of the index of cancer potential (J92) andof the adenosis index (J93) during setting in and chronic phases ofadenomyosis of the uterus or of the prostate, dysplasia, scrofula, andregression of mitotic neoplasia activity (see Table XXIII). TABLE XXIIIControl Observed data Patient Mini Maxi Indexes T₀ T₁ T₂ T₃ T₄ 13 10 30J93 3409 2143 617.87 1629 2117.60 6 10 J92 0.011 0.028 0.4315 0.172 0.0514 10 30 J93 407 223 1036 2118 407.42 6 10 J92 0.68 1.07 482 0.05 0.6815 10 30 J93 223 1036 2118 407 223.18 6 10 J92 1.07 482 0.05 0.68 1.0716 10 30 J93 54.53 510 3921.9 68715 2447.87 6 10 J92 0.401 0.009 0.002717 10 30 J93 18.61 34.03 25.87 23.35 6 10 J92 1.37 0.19 1.75 7.82 18 1030 J93 433.5 581.4 372.13 34.71 312.21 6 10 J92 1.621 9.099 3.9416 4.7950.34 19 10 30 J93 162 197.7 215.23 192 6 10 J92 47 6.781 19.049 0.82 2010 30 J93 29.46 1155 316.99 58.67 35.61 6 10 J92 2.45 0.14 2.31 1.343.94 21 10 30 J93 16.94 25.56 6 10 J92 12.47 5.62 22 10 30 J93 24.822680 47.96 6 10 J92 3.92 0.87 0.48 3.37 0.64

One notices an increase of the circulating cortisol index (J26) and ofthe adrenal cortex index (J28) during all the acute phases of thesummoning up of the adaptation syndrome, as well as during the prolongedphases whatever the nature of the infectious, meteorological,psychological or traumatic aggression (see Table XXIV) TABLE XXIVControl Observed data Patient Mini Maxi Indexes T₀ T₁ T₂ T₃ T₄ 23 3 7J26 13.61 11.18 2.7 3.3 J28 2.392 3.207 24 3 7 J26 36.88 11.2 7.89 37.0723.35 2.7 3.3 J28 12.33 5.823 2.84 13.47 5.84 25 3 7 J26 6.27 3.221.7115 10.94 39.47 2.7 3.3 J28 1.658 0.62 1.7768 0.883 1.98

On the other hand, one notices a characteristic decrease in the adenosisindex and of the apoptosis index (J42) during evolutionary spurts ofneoplasia affections. (see Table XXV). TABLEAU XXV Control Observed dataPatient Mini Maxi Index T₀ T₁ T₂ T₃ T₄ 26 0.3 0.7 J42 0.61 0.44 0.340.23 0.12 27 0.3 0.7 J42 0.54 0.34 0.25 0.16 0.09 28 0.3 0.7 J42 0.430.40 0.37 0.07 29 0.3 0.7 J42 0.48 0.20 0.18 0.16 0.13 30 0.3 0.7 J420.28 0.22 0.20 31 0.3 0.7 J42 0.56 0.31 0.28 0.21 0.20

One also observes a noticeable decrease in the fibrosis index (J8)during post-cicatricial tissular regeneration phases after surgicalinterventions, on one hand, and of the insulin (J54) index duringsetting in as well as evolutionary phases of insulin dependent as wellas non insulin dependent diabetes, on the other hand.

1. A method for evaluating the dynamic biological state of a patient,said method comprising, measuring several elements or substances presentin blood and interpreting results of performed measures, comprising thefollowing steps: (1°) providing the blood previously taken from apatient; (2°) determining in vitro, from said blood, hematic substancesas metabolic and/or tissular parameters: number of red blood cells (GR),number of leukocytes (GB), hemoglobin (HG), number of neutrophils,number of eosinophils, number of lymphocytes, number of monocytes,number of platelets, lactate dehydrogenase (LDH), creatine phosphokinase(CPK), thyroid-stimulating hormone (TSH), alkaline phosphatases, liver(H1 and H2), bone (01) and/or intestine (I1, I2 and I3) isoenzymes,osteocalcin, potassium and calcium, and optionally, at least one of thefollowing substances: carcinoembryonic antigen (CEA), one or severalCA15-3, CA125 and CA19-9 markers, acid phosphatases, in particularprostatic acid phosphatase (PAP), prostate specific antigen (PSA),hourly sedimentation rate (ESR₁), bihourly sedimentation rate (ESR₂),thyroid hormones, in particular triiodothyronine (FT3) and thyroxine(FT4), g-glutamyl transpeptidases, transaminases, chlorides and sodium,and adrenocorticotropic hormone (ACTH); (3°) measuring, from step (2°),at least one index selected from the group consisting of followingindexes J1-J157: J1 a so-called genital ratio index, which is a ratiored blood cells/leukocytes, J2 a so-called genital-thyroid ratio index,which is a ratio neutrophils/lymphocytes, J3 a so-called adaptationindex, which is a ratio eosinophils/monocytes, J3 being such thatJ3=eosinophils/monocytes=ACTH/FSH, J4 a so-called thyroid index, whichis a ratio LDH/CPK, J5 a so-called estrogenic index, which is a ratioTSH/osteocalcin, J6 a so-called growth index, which is a ratio boneisoenzymes of the alkaline phosphatases/osteocalcin, (O1/osteocalcin),J7 a so-called turnover index, which is a product TSH×O1 J8 a so-calledfibrosis index, J8 being defined by a relationJ8=(TSH)²(osteocalcin)³/100, J9 a so-called index of thyroidinvolvement, which is a ratio CA 15-3/CEA, J10 a so-called index offollicular involvement, which is a ratio CA 125/CEA, J11 a so-calledindex of metabolic-hypothalamic involvement, which is the ratioCA19-9/CEA, J12 a so-called pancreatic index, which is a ratio PAP/PSA,J13 a so-called global TRH index of adaptation, which is a ratioCA19-9/TSH, J14 a so-called index of leukocytes mobilization, J14 beingdefined by a relation J14=(platelets×neutrophils×HG)/(30×leukocytes),J15 a so-called index of platelets mobilization, J15 being defined by arelation J15=platelets/(60×red blood cells), J16 a so-called index ofthyroid reactivating activity, which is a ratio monocytes/lymphocytes,J17 a so-called structure/function ratio index, J17 being defined by arelationJ17=(neutrophils+basophils+monocytes)/(eosinophils+lymphocytes), J18 aso-called index of estrogenic fraction # 1, which is a ratiolymphocytes/osteocalcin, J19 a so-called index of estrogenic fraction#2, which is a ratio neutrophils/monocytes, J20 a so-called index ofmetabolic estrogenic fraction, which is a ratio LDH/osteocalcin, J21 aso-called index of thyroid mobilization of bone metabolism, which is aratio LDH/bone isoenzymes fraction of a alkaline phosphatases, J22 aso-called index of thyroid mobilization of bone endocrine metabolism,which is a ratio TSH/bone isoenzymes fraction of a alkalinephosphatases, J23 a so-called index of relative osteomuscular metabolicactivity, which is a ratio CPK/bone isoenzymes fraction of a alkalinephosphatases, J24 a so-called index of thyroid bone metabolic activity,which is a ratio CPK/osteocalcin, J25 a so-called catabolism/anabolismratio index, J25 being a ratio J2/J1, J26 a so-called index ofcirculating cortisol, J26 being a ratio J25/J3, J27 a so-calledandrogenic index, J27 being a ratio J1/J3, J28 a so-called adrenalcortex index, J28 being a ratio J26/J27, J29 a so-called index ofadrenal cortex permissiveness, J29 being a ratio J1/J27, J30 a so-calledindex of aromatization of estrogens, J30 being a ratio J29/J1, J31 aso-called level of catabolism, J31 being a ratio J4/J28, J32 a so-calledlevel of anabolism, J32 being a ratio J31/J25, J33 a so-called level ofmetabolic activity efficiency, J33 being defined by a relationJ33=(J32+J31)×100/2.25, J34 a so-called index of bone remodeling, whichis a product TSH×J6, J35 a so-called index of nuclear membrane activity,J35 being a ratio J5/J6, J36 a so-called adjusted growth index, J36being a ratio J6/J7, J37 a so-called anti-growth index, J37 being aratio 1/J36, J38 a so-called somatostatin index, J38 being a ratioJ37/J26, J39 a so-called prolactin index, J39 being defined by arelation J39=(J38/J6)×TSH, J40 a so-called level of membrane expansion,J40 being a product J31×J36, J41 a so-called level of structuralexpansion, J41 being a product J32×J35, J42 a so-called apoptosis index,J42 being a ratio J41/J40, J43 a so-called adjusted apoptosis index, J43being a ratio J42/J35, J44 a so-called level of membrane fracture, J44being defined by a relation J44=J33/(TSH×J7), J45 a so-called necrosisindex, J45 being a ratio J44/J42, J46 a so-called level of activity oftotal androgens, J46 being a product J5×J1 J47 a so-called rate ofadrenal cortex androgens, J47 being defined by a relationJ47=J46/(1+J27), J48 a so-called rate of genital androgens, J48 beingdefined by a relation J48=(J46−J47), J49 a so-called progesterone index,J49 being defined by a relation J49=J5/(J48×J3), J50 a so-called levelof activity of genital estrogens, J50 being defined by a relationJ50=J5/(1+J30), J51 a so-called rate of aromatized estrogens, J51 beingdefined by a relation J51=J5−J50, JJ53 a so-called folliculin index, J53being defined by a relation J53=20×(J5/J49), J54 a so-called insulinindex, J54 being defined by a relation J54=(100×J25)/(J7×TSH), J55 aso-called demyelinization index, J55 being defined by a relationJ55−J541(J36×J6), J56 a so-called index of DNA fracture, J56 beingdefined by a relation J56=(100×J5×J6×J41)/(J7×J35×J42×J45), J57 aso-called index of nucleocytoplasmic pathogenicity, J57 being defined bya relation J57=(1.7×J56)/J44, J58 a so-called index of cellularfracture, J58 being defined by a relation J58=2.5×J44×J56/J45, J59 aso-called index of carcinogenesis, J59 is a ratio J57/J42, J60 aso-called index of comparative carcinogenesis, J60 being defined by arelation J60=(10×J58)/J43, J61 a so-called index of active cellularpermeability, J61 being defined by a relation J61=J6×J34/J54, J62 aso-called index of adjusted active cellular permeability, J62 beingdefined by a relation J62=(J61×J29)/J26, J63 a so-called index ofpassive cellular permeability, J63 being defined by a relationJ63=J45×J35×J68×10 (wherein J68 is defined as indicated below), J64 aso-called index of active intracellular osmolar gradient, J64 beingdefined by a relation J64=100×J54×J40×J35/J3, J65 a so-called index ofadjusted active intracellular osmolar gradient, J65 being defined by arelation J65=(J64×J29)/J26, J66 a so-called index of passiveintracellular osmolar gradient, J66 being defined by a relationJ66=(10×J43×J53)/(J45×J8), J67 a so-called oxidation-reduction index,J67 being defined by a relation J67=(100×J45×J40×J41×J54)/(J71×J8×J38),(wherein J71 is defined as indicated below), J68 a so-called index ofcorticoadrenal adaptation/permissiveness, J68 being defined by arelation J68=J26−J29−J28, J69 a so-called adaptogenic index which is aratio K/Ca, J70 a so-called βMSH/αMSH index, (differentialmelanocyte-stimulating hormones), J70 being a ratio J4/J69, J71 aso-called apoptosis bis index, J71 being defined by a relationJ71=J35/(J36×J25), J72 a so-called amylosis index, J72 being defined bya relation J72=(J38×J53×J55×TSH)/(J4×J5×J54), J73 a so-called index ofamylosis risk, J73 being a ratio J8/J67, J74 a so-called index ofinsulin resistance, J74 being a ratio J38/J54, J75 a so-called upstreamindex # 1, J75 being a ratio J4/J9, J76 a so-called upstream index #2,J76 being a ratio J4/J10, J77 a so-called upstream index #3, J77 being aratio J4/J11, J78 a so-called global upstream index #1, J78 being aratio J75/J76, J79 a so-called global upstream index #2, J79 being aratio J75/J77, J80 a so-called global upstream index #3, J80 being aratio J76/J77, J81 a so-called index of thyroid output #1, J81 being aratio J4/TSH, J82 a so-called index of free radicals, J82 being a ratioJ67/J54, J83 a so-called adjusted index of free radicals, J83 beingdefined by a relation J83=(J67+J64)/(J54+J74), J84 a so-calledcomparative index of free radicals, J84 being defined by a relationJ84=(J67+(100×J40)/(J54+J74), J85 a so-called index of free radicalnocivity, J85 being defined by a relationJ85=((J82+J83+J84)×J56)/(3×J71), J86 a so-called adjusted apoptosisindex (B), J86 being a ratio J71/J35, J87 a so-called index of activehistamine, J87 being defined by a relationJ87=(eosinophils×platelets×J3)/J52, J88 a so-called index of potentialhistamine, J88 being defined by a relation J88=(J87×J63)/(potassium×J70)J89 a so-called TRH index, J89 being a ratio TSH/FT4, J90 a so-calledindex of relative intrathyroid TRH activity, which is a ratio FT3/FT4,J91 a so-called index of carcinogenic expansion, J91 being a ratioJ60/J59, J92 a so-called index of cancer potential, J92 being a productJ91×J54×J85, J93 a so-called adenosis index, J93 being a ratio J8/J91,J94 a so-called ischemia reperfusion index, J94 being defined by arelation J94=10×J34×J43/J33, J95 a so-called thrombogenic index, J95being defined by a relation J95=10×J34×J42×J45/J33, J96 a so-calledthrombotic index, J96 being defined by a relation J96=J95×J87×J1/10, J97a so-called adjusted genital ratio index, J97 being defined by arelation J97=(J14×Red cells)/(Leukocytes×J15)=J14×J1/J15, J98 aso-called musculotropic index, J98 being defined by a relationJ98=J97×(CPK/O1), J99 a so-called adjusted estrogenic index, J99 beingdefined by a relation J99=(J5×(osteocalcin+1)/(osteocalcin+1−J98)), J100a so-called genital androgeny index, J100 being defined by a relationJ100=(J98/J81)×J99×(J97)²/(J3+J97), J101 a so-called comparative genitalandrogeny index, J101 being defined by a relationJ101=(2×(TSH)²×CPK)/(J4×osteocalcin×01), J102 a so-called “starter”index, J102 being a ratio J14/J15, J103 a so-called adjusted index ofthyroid reactivating activity, J103 being a product J16×J2, J104 aso-called pro-inflammatory index, J104 being a product J103×J69, J105 aso-called index of inflammation, J105 being a product J104×J45, J106 aso-called comparative index of inflammation, J106 being defined by arelation J106=J105/(((ESR₂/2)+ESR₁)/2)/ESR₁, J107 a so-calledinterleukin 1 index, J107 being defined by a relationJ107=(J16×J38)/(J103×J37), J108 a so-called DHEA index, J108 beingdefined by a relation J108=(J29×J30×J47×J51×J98×1000)/(J49×J27×J100),J109 a so-called serotonin index, J109 being defined by a relationJ109=(10×J102)/(J54×J74), J110 a so-called adjusted demyelinizationindex, J110 being a product J55×J102, J111 a so-called expansivenessindex #1, J111 being a ratio J36/J35, J112 a so-called expansivenessindex #2, J112 being a ratio J40/J41, J113 a so-called globalexpansiveness index, J113 being defined by a relationJ113=(J111×J112)/J45, J114 a so-called ACTH index, J114 being a ratioJ108/J26, J115 a so-called PTH index, J115 being defined by a relationJ115=(calcium×osteocalcin×TSH)/J4, J116 a so-called index ofgonadotropic output, J116 being defined by a relation J116=1/(J×J53),J117 a so-called index of pelvic congestion, J117 being defined by arelation J117=(J59/J60)×(J94/J33), J118 a so-called index of splanchniccongestion, J118 being a ratio J117/J14, J119 a so-called growth scoreindex, J119 being defined by a relation J119=(J6×J37)/(J36×J38), J120 aso-called GH growth score index, J120 being defined by a relationJ120=(J6×J37)/J36, J121 a so-called TRH/TSH ratio index, J121 being aratio J72/J93, J122 a so-called index of thyroid efficiency, J122 beinga ratio J4/J2, J123 a so-called index of relative thyroid efficiency,J123 being a ratio J122/J81, J124 a so-called index of oxidation, J124being defined by a relation J124=(100×J36×J54×J122)/(J74×J26), J125 aso-called index of reduction, J125 being a ratio J124/J67, J126 aso-called pro-amyloid index, J126 being a product J125×J74, J127 aso-called index of amyloid risk, J127 being a ratio J8/J124, J128 aso-called index of thyroid output #2, J128 being a product J2×J4, J129 aso-called comparative index of thyroid output, J129 being a ratioJ128/J81, J130 a so-called index of estrogenic fraction #3, J130 being aratio 1/J1, J131 a so-called index of estrogenic fraction #4, J131 beinga product J18×J19, J132 a so-called index of estrogenic fraction #5,J132 being a product J19×J130, J133 a so-called general index ofestrogenic fraction, J133 being a product J18×J19×J130, J134 a so-calledindex of estrogenic fraction #6, J134 being defined by a relationJ134=1/(osteocalcin×J2), J135 a so-called index of estrogenic fraction#7, J135 being a product J18×J19×J134, J136 a so-called index ofestrogenic fraction #8, J136 being a ratio J2/osteocalcin, J137 aso-called general quantitative estrogenic index, J137 being a product(J18+J19)×(leukocytes/100), J138 a so-called index of specificestrogenic fraction, J138 being a product J5×(J98+1), J139 a so-calledcomparative estrogenic index #1, J139 being a ratio J133/(J5×100), J140a so-called comparative estrogenic index #2, J140 being a ratioJ133/(J99×100), J141 a so-called global comparative estrogenic index,J141 being a ratio J133/(J5×J99×100), J142 a so-called index ofsomatotropic estrogenic output, J142 being a ratio J133/J144 (where J144is defined as indicated below), J143 a so-called index of quantitativeorganotissular estrogenic output, J143 being a ratio J137/J144 (whereJ144 is defined below), J144 a so-called FSH index #1, J144 being aratio J114/J3, J145 a so-called LH index #1, J145 being a productJ114×J27, J146 a so-called FSH index #2, J146 being a ratio J145/J1,J147 a so-called LH index #2, J147 being a product J144×J1, J148 aso-called index of progesterone output, J148 being a ratio J49/J138,J149 a so-called ketonic index, J149 being a ratio J102/J54, J150 aso-called index of total subliminal TRH, J150 being a productTSH×(CA19-9)×J90, J151 a so-called index of active carcinogenesis, J151being a product J59×J113, J152 a so-called comparative index of activecarcinogenesis, J152 being a product J60×J113, J153 a so-calledgonadothyrotropic index, J153 being a ratio TSH/J2, J154 a so-calledindex of global tissular estrogenic fraction, J154 being a ratioJ140/J139, J155 a so-called index of muscle destruction, J155 being aratio J36/J101, J156 a so-called amyloid score index, J156 being definedby a relation J156=(J2×J53×J72×J94×J110×J126×J127)/(J4×J5×J67×J19×J20),J157 a so-called adjusted necrosis index, J157 being a product LDH×J45;and, (4°) comparing at least one of the J1-J157 indexes with thecorresponding result obtained according to steps (2°) and (3°) withhuman beings already recognized as being healthy, in order to appreciatedynamically the biological state of the patient to be tested.
 2. Amethod according to claim 1, wherein at least one abnormality is lookedfor at the level of indexes J1 to J157 of the patient.
 3. A methodaccording to claim 1, wherein (i) at least one index from J1 to J24 and(ii) at least one index from J25 to J157 are looked for in step (3°). 4.A method according to claim 1, wherein in step (3°) at least 8, 10 or 15indexes J are measured.
 5. A method according to claim 1, wherein instep (3°) at least a portion of indexes J1-J157, which constitute thescores of functions involved in at least one of symptomatology and/orpathology of the patient to be tested, is measured.
 6. A methodaccording to claim 5, wherein said scores of functions involved in thesymptomatology and/or pathology are selected from the group consistingof the scores of pregnancy, menstruation, cardiovascularity, thrombosis,Alzheimer's disease, atherosclerosis, cancer and sudden death risk.
 7. Amethod according to claim 1, wherein in step (4°) the indexes obtainedfor a patient to be tested are compared with corresponding median valuesdetermined from healthy subjects.
 8. A software product loadable inparticular in an internal memory of a computer, comprising portions ofcomputer code to perform the following steps: (3°) measuring, from step(2°), at least one index selected from the group consisting of followingindexes J1-J157: J1 a so-called genital ratio index, which is a ratiored blood cells/leukocytes, J2 a so-called genital-thyroid ratio index,which is a ratio neutrophils/lymphocytes, J3 a so-called adaptationindex, which is a ratio eosinophils/monocytes, J3 being such thatJ3=eosinophils/monocytes=ACTH/FSH, J4 a so-called thyroid index, whichis a ratio LDH/CPK, J5 a so-called estrogenic index, which is a ratioTSH/osteocalcin, J6 a so-called growth index, which is a ratio boneisoenzymes of the alkaline phosphatases/osteocalcin, (O1/osteocalcin),J7 a so-called turnover index, which is a product TSH×O1 J8 a so-calledfibrosis index, J8 being defined by a relationJ8=(TSH)²(osteocalcin)³/100, J9 a so-called index of thyroidinvolvement, which is a ratio CA 15-3/CEA, J10 a so-called index offollicular involvement, which is a ratio CA 125/CEA, J11 a so-calledindex of metabolic-hypothalamic involvement, which is a ratioCA19-9/CEA, J12 a so-called pancreatic index, which is a ratio PAP/PSA,J13 a so-called global TRH index of adaptation, which is a ratioCA19-9/TSH, J14 a so-called index of leukocytes mobilization, J14 beingdefined by a relation J14=(platelets×neutrophils×HG)/(30×leukocytes),J15 a so-called index of platelets mobilization, J15 being defined by arelation J15=platelets/(60×red blood cells), J16 a so-called index ofthyroid reactivating activity, which is a ratio monocytes/lymphocytes,J17 a so-called structure/function ratio index, J17 being defined by arelationJ17=(neutrophils+basophils+monocytes)/(eosinophils+lymphocytes), J18 aso-called index of estrogenic fraction # 1, which is a ratiolymphocytes/osteocalcin, J19 a so-called index of estrogenic fraction#2, which is a ratio neutrophils/monocytes, J20 a so-called index ofmetabolic estrogenic fraction, which is a ratio LDH/osteocalcin, J21 aso-called index of thyroid mobilization of bone metabolism, which is aratio LDH/bone isoenzymes fraction of a alkaline phosphatases, J22 aso-called index of thyroid mobilization of bone endocrine metabolism,which is a ratio TSH/bone isoenzymes fraction of a alkalinephosphatases, J23 a so-called index of relative osteomuscular metabolicactivity, which is a ratio CPK/bone isoenzymes fraction of a alkalinephosphatases, J24 a so-called index of thyroid bone metabolic activity,which is a ratio CPK/osteocalcin, J25 a so-called catabolism/anabolismratio index, J25 being a ratio J2/J1, J26 a so-called index ofcirculating cortisol, J26 being a ratio J25/J3, J27 a so-calledandrogenic index, J27 being a ratio J1/J3, J28 a so-called adrenalcortex index, J28 being a ratio J26/J27, J29 a so-called index ofadrenal cortex permissiveness, J29 being a ratio J1/J27, J30 a so-calledindex of aromatization of estrogens, J30 being a ratio J29/J1, J31 aso-called level of catabolism, J31 being a ratio J4/J28, J32 a so-calledlevel of anabolism, J32 being a ratio J31/J25, J33 a so-called level ofmetabolic activity efficiency, J33 being defined by a relationJ33=(J32+J31)×100/2.25, J34 a so-called index of bone remodeling, whichis a product TSH×J6, J35 a so-called index of nuclear membrane activity,J35 being a ratio J5/J6, J36 a so-called adjusted growth index, J36being a ratio J6/J7, J37 a so-called anti-growth index, J37 being aratio 1/J36, J38 a so-called somatostatin index, J38 being a ratioJ37/J26, J39 a so-called prolactin index, J39 being defined by arelation J39=(J38/J6)×TSH, J40 a so-called level of membrane expansion,J40 being a product J31×J36, J41 a so-called level of structuralexpansion, J41 being a product J32×J35, J42 a so-called apoptosis index,J42 being a ratio J41/J40, J43 a so-called adjusted apoptosis index, J43being a ratio J42/J35, J44 a so-called level of membrane fracture, J44being defined by a relation J44=J33/(TSH×J7), J45 a so-called necrosisindex, J45 being a ratio J44/J42, J46 a so-called level of activity oftotal androgens, J46 being a product J5×J1 J47 a so-called rate ofadrenal cortex androgens, J47 being defined by a relationJ47=J46/(1+J27), J48 a so-called rate of genital androgens, J48 beingdefined by a relation J48=(J46−J47), J49 a so-called progesterone index,J49 being defined by a relation J49=J5/(J48×J3), J50 a so-called levelof activity of genital estrogens, J50 being defined by a relationJ50=J5/(1+J30), J51 a so-called rate of aromatized estrogens, J51 beingdefined by a relation J51=J5−J50, JJ53 a so-called folliculin index, J53being defined by a relation J53=20×(J5/J49), J54 a so-called insulinindex, J54 being defined by a relation J54=(100×J25)/(J7×TSH), J55 aso-called demyelinization index, J55 being defined by a relationJ55−J541(J36×J6), J56 a so-called index of DNA fracture, J56 beingdefined by a relation J56=(100×J5×J6×J41)/(J7×J35×J42×J45), J57 aso-called index of nucleocytoplasmic pathogenicity, J57 being defined bya relation J57=(1.7×J56)/J44, J58 a so-called index of cellularfracture, J58 being defined by a relation J58=2.5×J44×J56/J45, J59 aso-called index of carcinogenesis, J59 is a ratio J57/J42, J60 aso-called index of comparative carcinogenesis, J60 being defined by arelation J60=(10×J58)/J43, J61 a so-called index of active cellularpermeability, J61 being defined by a relation J61=J6×J34/J54, J62 aso-called index of adjusted active cellular permeability, J62 beingdefined by a relation J62=(J61×J29)/J26, J63 a so-called index ofpassive cellular permeability, J63 being defined by a relationJ63=J45×J35×J68×10 (wherein J68 is defined as indicated below), J64 aso-called index of active intracellular osmolar gradient, J64 beingdefined by a relation J64=100×J54×J40×J35/J3, J65 a so-called index ofadjusted active intracellular osmolar gradient, J65 being defined by arelation J65=(J64×J29)/J26, J66 a so-called index of passiveintracellular osmolar gradient, J66 being defined by a relationJ66=(10×J43×J53)/(J45×J8), J67 a so-called oxidation-reduction index,J67 being defined by a relation J67=(100×J45×J40×J41×J54)/(J71×J8×J38),(wherein J71 is defined as indicated below), J68 a so-called index ofcorticoadrenal adaptation/permissiveness, J68 being defined by arelation J68=J26−J29−J28, J69 a so-called adaptogenic index which is aratio K/Ca, J70 a so-called βMSH/αMSH index, (differentialmelanocyte-stimulating hormones), J70 being a ratio J4/J69, J71 aso-called apoptosis bis index, J71 being defined by a relationJ71=J35/(J36×J25), J72 a so-called amylosis index, J72 being defined bya relation J72=(J38×J53×J55×TSH)/(J4×J5×J54), J73 a so-called index ofamylosis risk, J73 being a ratio J8/J67, J74 a so-called index ofinsulin resistance, J74 being a ratio J38/J54, J75 a so-called upstreamindex # 1, J75 being a ratio J4/J9, J76 a so-called upstream index #2,J76 being a ratio J4/J10, J77 a so-called upstream index #3, J77 being aratio J4/J11, J78 a so-called global upstream index #1, J78 being aratio J75/J76, J79 a so-called global upstream index #2, J79 being aratio J75/J77, J80 a so-called global upstream index #3, J80 being aratio J76/J77, J81 a so-called index of thyroid output #1, J81 being aratio J4/TSH, J82 a so-called index of free radicals, J82 being a ratioJ67/J54, J83 a so-called adjusted index of free radicals, J83 beingdefined by a relation J83=(J67+J64)/(J54+J74), J84 a so-calledcomparative index of free radicals, J84 being defined by a relationJ84=(J67+(100×J40)/(J54+J74), J85 a so-called index of free radicalnocivity, J85 being defined by a relationJ85=((J82+J83+J84)×J56)/(3×J71), J86 a so-called adjusted apoptosisindex (B), J86 being a ratio J71/J35, J87 a so-called index of activehistamine, J87 being defined by a relationJ87=(eosinophils×platelets×J3)/J52, J88 a so-called index of potentialhistamine, J88 being defined by a relation J88=(J87×J63)/(potassium×J70)J89 a so-called TRH index, J89 being a ratio TSH/FT4, J90 a so-calledindex of relative intrathyroid TRH activity, which is a ratio FT3/FT4,J91 a so-called index of carcinogenic expansion, J91 being a ratioJ60/J59, J92 a so-called index of cancer potential, J92 being a productJ91×J54×J85, J93 a so-called adenosis index, J93 being a ratio J8/J91,J94 a so-called ischemia reperfusion index, J94 being defined by arelation J94=10×J34×J43/J33, J95 a so-called thrombogenic index, J95being defined by a relation J95=10×J34×J42×J45/J33, J96 a so-calledthrombotic index, J96 being defined by a relation J96=J95×J87×J1/10, J97a so-called adjusted genital ratio index, J97 being defined by arelation J97=(J14×Red cells)/(Leukocytes×J15)=J14×J1/J15, J98 aso-called musculotropic index, J98 being defined by a relationJ98=J97×(CPK/O1), J99 a so-called adjusted estrogenic index, J99 beingdefined by a relation J99=(J5×(osteocalcin+1)/(osteocalcin+1−J98)), J100a so-called genital androgeny index, J100 being defined by a relationJ100=(J98/J81)×J99×(J97)²/(J3+J97), J101 a so-called comparative genitalandrogeny index, J101 being defined by a relationJ101=(2×(TSH)²×CPK)/(J4×osteocalcin×01), J102 a so-called “starter”index, J102 being a ratio J14/J15, J103 a so-called adjusted index ofthyroid reactivating activity, J103 being a product J16×J2, J104 aso-called pro-inflammatory index, J104 being a product J103×J69, J105 aso-called index of inflammation, J105 being a product J104×J45, J106 aso-called comparative index of inflammation, J106 being defined by arelation J106=J105/(((ESR₂/2)+ESR₁)/2)/ESR₁, J107 a so-calledinterleukin 1 index, J107 being defined by a relationJ107=(J16×J38)/(J103×J37), J108 a so-called DHEA index, J108 beingdefined by a relation J108=(J29×J30×J47×J51×J98×1000)/(J49×J27×J100),J109 a so-called serotonin index, J109 being defined by a relationJ109=(10×J102)/(J54×J74), J110 a so-called adjusted demyelinizationindex, J110 being a product J55×J102, J111 a so-called expansivenessindex #1, J111 being a ratio J36/J35, J112 a so-called expansivenessindex #2, J112 being a ratio J40/J41, J113 a so-called globalexpansiveness index, J113 being defined by a relationJ113=(J111×J112)/J45, J114 a so-called ACTH index, J114 being a ratioJ108/J26, J115 a so-called PTH index, J115 being defined by a relationJ115=(calcium×osteocalcin×TSH)/J4, J116 a so-called index ofgonadotropic output, J116 being defined by a relation J116=1/(J×J53),J117 a so-called index of pelvic congestion, J117 being defined by arelation J117=(J59/J60)×(J94/J33), J118 a so-called index of splanchniccongestion, J118 being a ratio J117/J14, J119 a so-called growth scoreindex, J119 being defined by a relation J119=(J6×J37)/(J36×J38), J120 aso-called GH growth score index, J120 being defined by a relationJ120=(J6×J37)/J36, J121 a so-called TRH/TSH ratio index, J121 being aratio J72/J93, J122 a so-called index of thyroid efficiency, J122 beinga ratio J4/J2, J123 a so-called index of relative thyroid efficiency,J123 being a ratio J122/J81, J124 a so-called index of oxidation, J124being defined by a relation J124=(100×J36×J54×J122)/(J74×J26), J125 aso-called index of reduction, J125 being a ratio J124/J67, J126 aso-called pro-amyloid index, J126 being a product J125×J74, J127 aso-called index of amyloid risk, J127 being a ratio J8/J124, J128 aso-called index of thyroid output #2, J128 being a product J2×J4, J129 aso-called comparative index of thyroid output, J129 being a ratioJ128/J81, J130 a so-called index of estrogenic fraction #3, J130 being aratio 1/J1, J131 a so-called index of estrogenic fraction #4, J131 beinga product J18×J19, J132 a so-called index of estrogenic fraction #5,J132 being a product J19×J130, J133 a so-called general index ofestrogenic fraction, J133 being a product J18×J19×J130, J134 a so-calledindex of estrogenic fraction #6, J134 being defined by a relationJ134=1/(osteocalcin×J2), J135 a so-called index of estrogenic fraction#7, J135 being a product J18×J19×J134, J136 a so-called index ofestrogenic fraction #8, J136 being a ratio J2/osteocalcin, J137 aso-called general quantitative estrogenic index, J137 being a product(J18+J19)×(leukocytes/100), J138 a so-called index of specificestrogenic fraction, J138 being a product J5×(J98+1), J139 a so-calledcomparative estrogenic index #1, J139 being a ratio J133/(J5×100), J140a so-called comparative estrogenic index #2, J140 being a ratioJ133/(J99×100), J141 a so-called global comparative estrogenic index,J141 being a ratio J133/(J5×J99×100), J142 a so-called index ofsomatotropic estrogenic output, J142 being a ratio J133/J144 (where J144is defined as indicated below), J143 a so-called index of quantitativeorganotissular estrogenic output, J143 being a ratio J137/J144 (whereJ144 is defined below), J144 a so-called FSH index #1, J144 being aratio J114/J3, J145 a so-called LH index #1, J145 being a productJ114×J27, J146 a so-called FSH index #2, J146 being a ratio J145/J1,J147 a so-called LH index #2, J147 being a product J144×J1, J148 aso-called index of progesterone output, J148 being a ratio J49/J138,J149 a so-called ketonic index, J149 being a ratio J102/J54, J150 aso-called index of total subliminal TRH, J150 being a productTSH×(CA19-9)×J90, J151 a so-called index of active carcinogenesis, J151being a product J59×J113, J152 a so-called comparative index of activecarcinogenesis, J152 being a product J60×J113, J153 a so-calledgonadothyrotropic index, J153 being a ratio TSH/J2, J154 a so-calledindex of global tissular estrogenic fraction, J154 being a ratioJ140/J139, J155 a so-called index of muscle destruction, J155 being aratio J36/J101, J156 a so-called amyloid score index, J156 being definedby a relation J156=(J2×J53×J72×J94×J110×J126×J127)/(J4×J5×J67×J19×J20),J157 a so-called adjusted necrosis index, J157 being a product LDH×J45;and, (4°) comparing at least one of the J1-J157 indexes with thecorresponding result obtained according to steps (2°) and (3°) withhuman beings already recognized as being healthy, in order to appreciatedynamically the biological state of the patient to be tested.
 9. Asoftware product according to claim 8, comprising (A) a form field forentering (i) the patient's name or code, (ii) his age, and (iii) hissex, on the one hand, and any known treatment followed by said patientformerly or at the present time, on the other hand; (B) a form field forentering (iv) one or several hematic parameters measured in vitro fromthe blood of the patient and (v) the date of the measures; (C) a fieldincluding all the indexes from J1 to J157, (vii) their calculation modeand (viii) their median values determined from human beings who arerecognized as healthy subjects; (D) a command for (ix) the calculationof one index J, of several indexes J or the totality of indexes from thehematic parameters of said field (B) obtained from the blood of thepatient to be tested, and (x) for the comparison of the obtained valuefor at least one of said indexes J with its median value of field (C);and, (E) means for classifying, visualizing, editing and/or printing theobtained result by implementing command (D) starting from fields (A),(B), and (C).
 10. A software product according to claim 9, wherein eachmedian value of an index J in an interval of normal values previouslydetermined from subjects recognized as being healthy.
 11. A softwareproduct according to claim 10, which comprises an instruction forrecognizing and flagging up any abnormality constituted by a value of anindex J which stands away from its median value or interval thereof. 12.A software product according to claim 9, which comprises an instructionfor recognizing and flagging up any abnormality constituted by a valueof an index J which stands away from its median value or intervalthereof.